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ABSTRACT 
 
Title: A Comparative Study To Evaluate The Efficacy Of Oral Lactoferrin Fortified 
Bovine Colostrum With Oral Iron In The Treatment Of Iron Deficiency 
Anaemia 
 
Introduction: Iron deficiency affects more than 2 billion people globally, with greater 
prevalence noted amongst women and children. Oral ferrous sulphate, the most commonly 
prescribed drug for treating this condition, is associated with 25 to 40% incidence of 
adverse drug reactions.  This along with its variable bioavailability emphasise a need for 
better oral formulations. Lactoferrin, a glycoprotein structurally resembling transferrin, is 
believed to play a role in iron absorption. Hence a study was designed to evaluate the 
efficacy of oral lactoferrin fortified bovine colostrum in the treatment of iron deficiency 
anaemia. 
Aim: To compare the efficacy of oral lactoferrin fortified bovine colostrum (as a single 
agent and in combination with ferrous sulphate) with oral ferrous sulphate in treating iron 
deficiency anaemia 
Methodology: A prospective randomized open–labelled study was designed with 3 parallel 
arms and a study population of 68 anaemic women. The control arm was given oral ferrous 
sulphate 333 mg (containing 100 mg elemental iron) OD, the study arm was given 
lactoferrin fortified bovine colostrum 2g OD , while the combination arm received both. All 
treatment regimens were for 30 days. Baseline and post-therapy haemoglobin and iron 
parameters were assessed and analysed using student’s paired t-test, ANOVA and Wilcoxon 
signed rank test. 
Results: There was significant improvement in haemoglobin and iron parameters from 
baseline to post-therapy in the arms that received lactoferrin fortified bovine colostrum and 
was associated with fewer adverse events. The improvement in haemoglobin and iron 
parameters in the combination arm were comparable to the study arm. There were fewer 
adverse effects in the arms that received lactoferrin fortified bovine colostrum compared to 
ferrous sulphate arm. 
Conclusion: Hence lactoferrin fortified bovine colostrum is a safe and efficacious treatment 
modality for iron deficiency anaemia and is associated with fewer adverse effects compared 
to oral ferrous sulphate. 
Keywords: Iron Deficiency Anaemia, Lactoferrin fortified bovine colostrum, ferrous 
sulphate. 
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INTRODUCTION 
 
Iron is an essential element required by the body for normal tissue 
oxygenation. Iron deficiency is the most common nutritional deficiency which 
affects more than 2 billion people worldwide.[1] In India, the prevalence of iron 
deficiency anaemia is as high as 74.3%, with women and children being affected 
more than the general population.[2] In Tamil Nadu alone, it affects 55.6% of 
women.[3]  
Iron deficiency anaemia is associated with easy fatigability and decreased 
work performance in adults.[1] Pregnant women with iron deficiency anaemia have 
increased morbidities and mortality during their antenatal period with poor 
outcomes.[3] Children with iron deficiency anaemia manifest psychomotor 
developmental delays.[1] Hence it is essential to rectify the iron deficiency in an 
individual. 
 The current treatment modalities available such as oral ferrous sulphate and 
parenteral iron are fraught with many adverse drug reactions which lead to poor 
patient compliance and hence poor response to therapy.[4] 
 Our search for an effective, patient friendly treatment of iron deficiency 
anaemia led us to lactoferrin. Lactoferrin, a glycopeptide found in colostrum, 
belonging to transferrin family, is involved in absorption of iron from dietary 
sources.[5] Hence, supplementing lactoferrin should increase iron absorption. Its 
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efficacy in increasing iron parameters in pregnant women was proven in a few 
European studies.[77,78,83] 
 Lactoferrin fortified bovine colostrum (Laktrum) is a nutritional supplement 
available in India, with a high lactoferrin content. It is devoid of unpleasant side 
effects and therefore may improve patient compliance and result in better 
therapeutic outcomes. Hence a study was designed to assess the efficacy of 
lactoferrin fortified bovine colostrum in treating iron deficiency anaemia in Indian 
women. 
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REVIEW OF LITERATURE 
IRON 
 Iron is a metallic mineral that constitutes most of Earth’s Inner and outer 
core and is the fourth most abundant element on the Earth’s crust. The 
magnetosphere generated by the spinning iron at the centre of the Earth is 
responsible for protecting the life force on earth from harmful solar winds and 
radiation.[6] 
 Three and a half billion years ago, life started on this planet in an aerobic, 
hyperthermic, hyperbaric environment with the transfer of electrons from mineral 
sources such as iron to electron acceptors.[6] This process gave rise to the building 
blocks of life in the form of various carbon containing organic compounds. Iron’s 
crucial role in the creation of organic compounds is best summed up by R.J.P. 
William’s prophetic remark, expressed in Nature, 1990, “Energy capture based on 
Fe/S compounds, now and perhaps before there was life, is as important as DNA in 
life’s history.” 
 Over the next 1.5 billion years, photosensitizing cyanobacteria led to the 
insidious addition of oxygen into the atmosphere which dramatically changed life on 
earth. The entry of oxygen revolutionized the planet’s metabolic numbers from an 
anaerobic reaction that generated a mere 2 ATPs per molecule of glucose to 36 ATP 
per molecule of glucose. The presence of oxygen also led to a meandering course of 
iron metabolism as ferrous iron found itself being oxidized to insoluble ferric iron 
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This change in the form of iron availability had profound effects that is evident even 
now where all organisms struggle to acquire, transfer and store this precious metal, 
iron.  
Iron Absorption and Metabolism in Lower Organisms  
 Iron, in the presence of oxygen, forms oxides which are insoluble and hence 
unavailable for use by living matter. Organisms have overcome this by way of 
various cellular mechanisms that facilitate the absorption of iron in a biologically 
useful form. Microbes secrete small, high-affinity iron chelating molecules known 
as siderophores which enable them to capture iron from their environment.[7] Yet, 
others like yeast have devised mechanisms to reduce iron from its insoluble ferric 
form to soluble ferrous form.[8] 
Iron Absorption and Metabolism in Higher Organisms 
   The mechanisms for iron absorption and utilization in higher organisms 
parallels those found in lower organisms. Iron absorption and metabolism has 
evolved to a complex, tightly regulated mechanism in humans. As early as 1938, it 
was established by Mccance and Widowson that iron is not excreted by the body.[9] 
It was understood that iron homeostasis in man is unique as it is regulated by its 
absorption and not by its metabolism or excretion. It was only during the turn of the 
century, 60 years later, after the discovery of new players in the iron-absorption 
pathway that some clarity on this subject has emerged.  
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DIETARY IRON 
 Humans ingest approximately 12 to 18 mg/day of dietary iron, of which only 
1 to 2 mg is absorbed. Adult men and non-menstruating women require 13 
mg/kg/day of iron while menstruating women require 21 mg/kg/day. The iron 
requirement can go up to 80 mg/kg/day in the last two trimesters of pregnancy.[10]  
Iron may be ingested in two forms, either ‘Haeme’ iron or ‘Non-haeme’ iron. 
Haeme iron is sourced from the consumption of myoglobin and haemoglobin found 
in meat, fish and poultry. It accounts for 10–15% of the total iron intake in meat-
eating populations and is responsible for more than 40% of the iron absorbed by the 
body. Non-haeme iron is sourced in diets rich in plant based foods such as cereals, 
legumes, pulses, fruits and vegetables. Non-haeme iron may exist as food ferritin, 
iron minerals or iron complexes. Non-haeme iron requires acid digestion and is 
dependent on dietary enhancers and inhibitors while haeme iron is minimally 
affected by dietary factors. [11] [Table 1] 
Table 1: Factors Modifying Dietary Iron Absorption 
Type of Dietary Iron Inhibitors Enhancers 
Haeme iron None None 
Non-Haeme iron Calcium 
Fibre 
Phytates, Tannins 
Polyphenols from Tea/Coffee/Wine 
Antacids 
Ascorbate 
Citrate 
Amino Acids 
 
 
16 
Iron Absorption by Enterocytes 
 The extraction of iron from either haeme or non-haeme sources follow two 
convergent pathways as discussed below. Iron absorption occurs in the duodenum 
and upper jejunum. Two transport proteins, DMT-1 (Divalent Metal Transporter) 
and HCP-1 (Haeme carrier Protein) have been identified and implicated in the 
transport of iron to the cytosol of the enterocyte. 
Absorption of Non-Haeme Iron by Enterocyte 
 Iron from non-haeme sources exist as ferric iron. For absorption of non-
haeme iron, the ferric iron is first reduced to the ferrous form by duodenal 
cytochrome b (dcytb). Dcytb is an ascorbate-dependant ferric reductase present in 
the duodenum. [12] The reduced ferrous iron then enters the duodenal enterocytes 
via the apical membrane with the help of Divalent Metal Transporter-1 (DMT-1). 
DMT-1 is a glycoprotein with 12 transmembrane domains with a broad range of 
divalent substrates such as Cd2+, Pb2+, Zn2+, Mn2+, Cu2+, and Co2+.[13] DMT-1 is 
expressed by the intestinal cells concomitantly with dcytb and is upregulated in the 
presence of iron deficiency.[14] Hence the uptake of iron from non-haeme sources 
requires its reduction by dcytb followed by its transport into the enterocyte by  
DMT-1.[Figure 1 a] 
Absorption of Haeme Iron by Enterocytes 
 Due to its hydrophobic nature, haeme was thought to passively diffuse into 
the enterocyte but this has been disproved by the discovery of Haeme carrier 
protein-1 (HCP-1). HCP-1 (a.k.a SLC46A1) is expressed abundantly in the 
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duodenal enterocytes and transports iron within haeme from the apical membrane to 
the cytosol of the enterocyte. The expression of HCP-1 appears to be regulated by 
iron levels. The transport of haeme by HCP-1 is a saturable process.[15] Once inside 
the cell, haeme acts as a substrate for Haeme Oxygenase-1(HOx-1), an enzyme 
discovered by Tenhunen et al.[Figure 1b]  Haeme Oxygenase-1 attacks the α-
methylene bridge of the haeme macro cycle in an oxygen-dependent manner and 
causes the release of iron along with biliverdin and carbon monoxide.[6,16] 
Export of Iron from Enterocyte 
 Iron in the enterocyte can either be stored as ferritin or exported to the blood 
to be carried to tissues by transferrin. The export of iron from the enterocyte is 
facilitated by an iron transporter known as ferroportin. Ferroportin (aka SLC40A1) 
was first identified by positional cloning of the causative gene causing hypochromic 
anaemia in ‘Weissherbst’ zebrafish.[17] Subsequently, ferroportin was found in the 
polarized basolateral membrane of duodenal enterocytes, basal cells of the placental 
syncytiotrophoblasts and the cytosol of cells of the reticuloendothelial system. 
Human ferroportin is encoded by chromosome 2q and consists of 571 amino acids 
with conserved hairpin loop sequences.  It has been established as a major 
transporter, if not the sole transporter of iron and transports iron in the ferrous 
state.[18] 
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Transfer of Iron to Transferrin 
 As iron can only be transported in the ferric state by transferrin, ferroportin is 
often associated with proteins that serve as ferrioxidases. One such protein is 
Hephaestin, which is a membrane bound multi-copper oxidase analogous to 
ceruloplasmin. Hephaestin is expressed in the intestinal villi whereas ceruloplasmin 
is found in macrophages, liver, brain, lung and astrocytes.[17] The former is crucial 
in the initial stage of incorporation of iron in transferrin, while the latter takes over 
that function at a later stage. Animal studies in mice with aceruloplasminemia 
suggest a facilitatory role of ceruloplasmin in the binding of iron to transferrin.[10] 
Iron Transport by Transferrin 
 Ferric iron in the plasma is scavenged by transferrin (Tf) and delivered to 
tissues that either utilize or store the iron. Transferrin, an 80Kda glycoprotein 
encoded by chromosome 3q21-25, is synthesized by hepatocytes and secreted into 
the plasma. Transferrin is composed of a single bilobed chain that contain N-
(Amino) and C-(Carboxy) lobes, each of which have two domains, referred to as  
N1, N2, C1, and C2. Each transferrin molecule has two iron binding domains that 
are located in the clefts between the two lobes. The binding and release of iron 
occurs by conformational changes brought about by the twisting of N1, N2, CI and 
C2 resulting in the opening or closing of subdomains of each lobe.[19] 
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Iron-bound transferrin normally has only one-third of its sites occupied, which 
facilitates further sequestration of any potentially toxic iron in the plasma. Hence 
transferrin plays a protective role by reducing the generation of free radicals by 
sequestering free iron in the plasma.  
 Transferrin is responsible for the transport of both endogenous and 
exogenous iron, a dynamic function it performs over 10 times a day in order to 
sustain normal erythropoiesis. It is astounding that although transferrin accounts for 
only 0.1% of the body’s iron (~3mg), it is responsible for the transport of 30 mg of 
iron that is used to synthesize haemoglobin for 200 billion RBCs.[6] Circulating 
iron-bound-transferrin is the only source of iron to most cells except mature RBCs, 
enterocytes and the brain. 
Transport of Fe-Transferrin into Cells 
 Great care has to be exercised in the transport of transferrin bound iron into 
the cytosol of the cell. The cell has to extract the tightly bound iron from transferrin, 
all the while ensuring that no harmful free radicals are generated in the process. The 
unbound potentially toxic iron will then have to be delivered to the site of functional 
assimilation in the cell which is usually the mitochondrion.[6] 
Transferrin Receptors 
 Iron-bound transferrin (Fe-Tf) binds to a highly specific membrane bound 
transferrin receptor (TfR) that serves as a gatekeeper, regulating the entry of iron 
into cells that either utilize or store it. Cells that have a requirement for iron, exhibit 
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transferrin receptors at their cell membrane. There are two types of transferrin 
receptors, TfR1 and TfR2. Both are polypeptides with 3 domains; an apical domain, 
a protease-like domain and a helical domain. TfR1 is found in all tissues other than 
mature RBCs. Its expression is regulated by cellular iron level via HFE (human 
hemochromatosis protein). TfR2 is found mainly in hepatocytes and duodenal cells. 
It has a lower affinity for Fe-Tf than TfR1 and is not regulated by cellular iron 
levels.  
 TfR1 knockout mice are embryologically lethal while its deficiency results in 
low tissue iron levels. Deficiency of TfR2 leads to the development of 
hemochromatosis which is a state of iron overload. TfR2 regulates the expression of 
hepcidin, which in turn is considered to be the master regulator in iron 
homeostasis.[17] 
Fe-Tf-TfR Internalization 
 Receptor mediated uptake of Fe-Tf is a complex process involving targeting, 
signalling, docking and movement of the complex into the cell. It is initiated when 2 
molecules of Fe-Tf bind to the arginine-glycine-aspartate sequence of the helical 
domain of the transferrin receptor.[9] The signal for internalization of the Fe-Tf-TfR 
complex is provided by the tyrosine moiety located in the N-terminal of the 
cytoplasmic domain of TfR. 
  A clathrin mediated endocytosis of Fe-Tf-TfR complex occurs, followed by 
fusion of the clathrin coated vesicle with an endosome which is referred to as the 
sorting endosome. The next fate of Fe-Transferrin-TfR complex has not been lucidly 
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chalked out. It has been observed to exist in a collection of tubular structures 
associated with microtubules known as the endosomal recycling compartment 
(ERC).[6] 
Release of Iron from Fe-Transferrin-TfR Complex 
 The exact mechanism of release of iron from the Fe-Transferrin-TfR 
complex is hazy though it has been proposed that the acidic pH of endosomes is 
responsible for the dissociation of iron from the Fe-Transferrin-TfR complex. Iron 
free Transferrin-TfR exits the ERC and resurfaces back to the plasma membrane to 
ferry another load of iron. 
 Meanwhile, the iron in the endosome is reduced to its ferrous form by a 
ferric reductase. One such ferric reductase, STEAP3 has been found to perform this 
function in erythroid precursor cells.[6] The reduced iron is transported out to the 
cytosol by means of another divalent metal transport protein. The iron is sent to the 
mitochondria for utilization in metabolic processes or is stored as ferritin.  
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Figure 1: Absorption of Dietary Iron [87] 
1. Reduction of non-haeme ferric iron to ferrous iron by Duodenal cytochrome 
b (Dcytb) 
2. Transport of reduced iron into enterocyte by Divalent Metal Transporter 
(DMT-1) 
3. Transport of iron by Haeme Carrier Protein (HCP-1). Release of iron from 
haeme iron by haemeoxygenase-1 (HOx-1) 
4. Transport of iron from enterocyte to plasma ferritin by Ferroportin and 
Haephestin. 
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FERRITIN 
 The storage form of iron is ferritin, which is a ubiquitous spherical protein 
found in the mitochondria, cytosol, and nucleus of cells as well as in the serum. It is 
formed by the assembly of 24 subunits consisting of a varied ratio of H (heavy) and 
L (light) chains, both encoded by different genes. The subunits of ferritin assemble 
into a shell like structure with an 8nm central core capable of housing 4500 
molecules of iron as ferric oxy-hydroxide phosphate. Ferritin may exist as tissue 
ferritin, serum ferritin or mitochondrial ferritin. 
Tissue Ferritin 
 A specialized protein, Poly R (c)-Binding-protein-1(PCBP-1) chaperones 
iron from the cytosol to the core of ferritin. The L-subunit is responsible for the 
uptake of iron into the ferritin core. The ferroxidase activity of H-subunit is 
responsible for the oxidation of Fe2+ enabling mineralization of iron within the 
protein. The ratio of H to L varies from tissue to tissue. Heart cells and neurons 
exhibit a predominance of H subunit while L-subunits are predominantly expressed 
by the liver and spleen.[17] 
Serum Ferritin 
 A glycosylated form of ferritin composed predominantly of L subunits can 
be found in the circulation. As the iron content of serum ferritin is low, it is not 
expected to play a major role in iron storage or transport. It serves as a highly 
specific bio-marker of tissue iron stores. The normal serum ferritin levels range from 
15 to 150 microgram per litre. Serum ferritin levels help differentiate iron deficiency 
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anaemia from anaemia of chronic disease as in the latter case, ferritin stores will be 
normal. [17]   
Mitochondrial Ferritin 
 Mitochondrial ferritin is synthesized in the cytosol as a precursor polypeptide 
that is later targeted into mitochondria by an N-terminal leader sequence. It does not 
play a major role in the utilization of iron by the mitochondria though its expression 
is significantly increased in patients with sideroblastic anaemia.[17] 
Iron Utilization 
 Iron from ferritin can be mobilized as and when required and utilized only by 
its degradation. This may occur by two pathways, either a lysosomal or a 
proteosomal pathway. A deficit of iron must be there to trigger off either of the 
pathways. The lysosomal pathway leads to the complete lysis of ferritin followed by 
the release of its iron stores. For utilization of iron outside the storage cell, ferritin is 
transported with the help of ferroportin. This is particularly evident in macrophages. 
In the proteosomal pathway, the export of ferritin-derived-iron from the proteosome 
leads to monoubiquitination and degradation of the remnant apo-ferritin. In either 
case, the structured assembly of ferritin is destroyed in order to utilize the iron stores 
of ferritin. The ferritin-derived-iron is utilized for the running of the metabolic 
machinery of a cell rather than for erythropoiesis. Iron for erythropoiesis is derived 
directly from transferrin, the uptake of which is facilitated by the expression of 
soluble transferrin receptors on the bone marrow cells.[17]  
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Iron Regulation 
 The fluctuation of iron between ferrous and ferric states is a double edged 
sword, as the character of iron that facilitates electron transport in cellular 
respiration is also responsible for the generation of toxic labile ions. Most 
cytoplasmic iron exists in the ferrous state which on losing an electron forms toxic 
free radicals. Fenton reaction which occurs when ferrous iron interacts with H2O2 
generates ferric ion, OH- and hydroxyl radicals. These free radicals may result in 
lipid peroxidation and oxidative damage to macromolecules found in their vicinity. 
Hence cellular and plasma iron levels have to be tightly regulated. 
 The absorption of iron accounts for a mere fraction of the iron in the body 
with over 90% arising from the recycling of senescent RBCs. In an iron deficient 
state, the body increases its iron absorption by 3 to 5 folds. On the contrary, in an 
iron overloaded state, the body adopts the ‘mucosal block phenomena’ where iron 
bound to apo-ferritin in an enterocyte is shed off from the GIT along with the gastric 
epithelial cells. When there is excess of iron, ferroportin fails to transport absorbed 
iron out of the enterocyte.[6] 
 Much of the regulatory mechanisms are directed towards the release of 
stored iron, its transport and its recycling from cellular sources. Currently, the main 
factor regulating these processes is Hepcidin. It is secreted by the liver as a 25 amino 
acid peptide hormone. Hepcidin levels are decreased in hypoxia and anaemia and 
are increased in the presence of iron and inflammation. Hepcidin binds to ferroportin 
resulting in its internalization and degradation thereby preventing the entry of iron to 
plasma.[6] Conversely, decreased expression of hepcidin leads to increased surface 
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expression of ferroportin and thereby increased iron absorption. Hepcidin 
transcription, in turn, is regulated by the SMAD-4 mediated BMP (Bone 
Morphogenic Protein) receptor signalling pathway via other proteins such as HFE 
and Hemojuvelin.[10,20] Certain cytokines such as IL-6 are also believed to 
regulate its expression.[17] 
 Other proteins such as IRP-1, IRP-2 (Iron Response Proteins) bind to IRE 
(Iron Responsive Elements) in the untranslated regions of mRNA of regulatory 
proteins and are responsible for regulating the expression of key proteins in iron 
homeostasis.[6] 
Role of IL-6 in Iron Regulation 
 IL-6 is believed to a play a role in iron homeostasis by both a hepcidin 
dependant and independent pathway. Increased levels of IL-6 result in an increased 
transcription of hepcidin by hepatocytes. This results in greater degradation of 
ferroportin resulting in less iron transfer from the enterocytes.  Increased IL-6 can 
also directly cause the down-regulation of ferroportin mRNA expression resulting in 
decreased iron absorption.[21] 
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ROLE OF IRON IN THE BODY 
  The human body contains 3 to 4 g of iron, 60% of which is found circulating 
in the blood in the form of haemoglobin, 15% as myoglobin and the remaining 25% 
is stored as ferritin.[22] Iron, by virtue of being a constituent of various proteins and 
enzymes, plays an essential role in a wide spectrum of biological processes ranging 
from tissue oxygenation, energy metabolism to bactericidal actions of the immune 
system. 
 
Role of Iron in Tissue Oxygenation 
 The importance of tissue oxygenation was stressed by J.B.S. Haldane who 
stated that, “Anoxia not only breaks the machine but also wrecks the machinery”. 
 Tissue oxygenation is a process where oxygen from the lungs is transported 
to the cells of the tissues with the help of haemoglobin found in red blood cells. Iron 
in the ferrous state is capable of carrying oxygen, while iron in deoxygenated 
haemoglobin exists in the ferric state. Thus iron found in the porphyrin ring of 
haemoglobin is crucial for the iron carrying capacity of haemoglobin. Not only is 
iron important for the functioning of haemoglobin, but adequate iron levels are 
required for normal erythropoiesis. A study done in 1964 by Noyes et al., found that 
90% of injected radio iron could be traced to haeme from the bone marrow within an 
hour. In iron deficiency, the haemoglobin content of RBC is reduced resulting in 
their microcytic hypochromicity.[6]  
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Role of Iron in Cellular Metabolism/ Respiration  
 The transfer of electrons to oxygen by ferrous iron and vice versa is the basis 
for the electron transport chain that generates ATP required for cellular 
functioning.[24] Iron is required by enzymes such as aconitase, succinate 
dehydrogenase, isocitrate dehydrogenase of the citric acid cycle.[6,23] Hence 
cellular respiration would come to a standstill if it were not for iron. 
 Iron is also an important constituent of various enzyme systems notably the 
cytochrome oxidases that mediate the metabolism of various endogenous and 
exogenous compounds. 
Role of Iron in DNA Metabolism 
 The synthesis of DNA requires the conversion of ribonucleotides to 
deoxyribonucleotide by ribonucleotide reductase which requires iron for its 
optimum action. Iron serves as a co factor for xanthine oxidase which is responsible 
for the catabolism of purines. Hence the presence of iron is crucial for normal 
synthesis of DNA and its degradation.[23] 
Role of Iron in CNS 
 In addition to its role in neuronal metabolism, iron is a constituent of an 
enzyme known as protoheamoxygenase. This enzyme is located in oligodendria and 
is responsible for cholesterol synthesis required for myelination in the CNS. Iron is 
also an important constituent of monoamine oxidase and a co factor for tryptophan 
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hydroxylase, enzymes which are crucial for the metabolism of neurotransmitters. 
Iron deficient individuals exhibit altered GABA metabolism and a downregulation 
of dopamine receptors.[23, 24] 
Antimicrobial Actions of Iron  
 Just as higher organisms, lower organisms require iron for their functioning. 
Hence it is logical to assume that the lack of iron plays a protective role against 
invading organisms. Our body responds to invasion by microbes by regulating iron 
trafficking which results in anaemia of chronic disease. On the other hand, certain 
microbicidal enzymes such as catalase and myeloperoxidase that are released by 
neutrophils during an acute infection require iron for their optimum activity. Iron 
plays a regulatory role both in specific and non-specific immunity by enhancing T-
cell activation.[23] Hence optimal iron levels are required for the antimicrobial 
actions of iron. 
Other Roles of Iron in the Body 
 Iron plays versatile roles in various enzymatic reactions. Haeme synthase 
and uroporphyrinogen decarboxylase in porphyrin metabolism are under feedback 
control of iron. Iron is a constituent of pigment synthesizing enzymes such as 
phenylalanine hydroxylase and homogentistic oxidase. The metabolism of 
phenylalanine is closely intertwined with that of catecholamines and thyroxine, 
deviations of which can cause endocrinal changes.[23] 
 Hence it is evident that iron plays a multi-faceted role in tissue oxygenation 
and metabolism and inarguably its deficiency will have undesirable effects.   
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IRON DEFICIENCY ANAEMIA 
 Iron deficiency (sideropenia or hypoferrimia) is one of the most common 
nutritional disorders worldwide that affects over 2 billion people.[1] WHO estimates 
a prevalence of iron deficiency anaemia to be between 25% and 43%  in developing 
countries.[25, 26][Figure 1.] In India, the prevalence is as high as 74.3%, with 
women and children being affected more than the general population.[2] 
 Iron deficiency is a condition where there is a dearth of mobilizable iron 
stores in the body. This occurs when the absorption of iron is insufficient to meet the 
demands of the body. An increase demand for iron is seen in people living in high 
altitudes, growing children and pregnant women. The deficiency of iron manifests as 
a wide spectrum of disease from the asymptomatic latent iron deficiency to the 
symptomatic iron deficiency anaemia. Mild to moderate forms of iron deficits show 
functional tissue impairment even in the absence of anaemia. The more severe 
stages of iron deficiency are associated with anaemia. Hence iron deficiency 
anaemia is a subset of iron deficiency. 
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DEFINITION OF ANAEMIA 
 An individual is said to be anaemic when his/her haemoglobin falls under 2 
standard deviation of the mean haemoglobin of a population of same age, sex and 
altitude. WHO defines anaemia as a haemoglobin value less than 11 g/dl (at sea 
level). [4] ICMR has categorized the severity of iron deficiency based on 
haemoglobin levels as mild, moderate and severe.[27][Table 2] 
Table 2: Categorization of Anaemia Based on Haemoglobin Levels 
Severity Haemoglobin Concentration (g/dl) 
Mild 8-11 
Moderate 5-8 
Severe <5 
 
 Such a categorization proves to be a useful tool in deciding appropriate 
treatment modalities and comprehensive evaluation of the condition. 
 The following pages discuss the aetiology, clinical features, diagnosis and 
current treatment available for iron deficiency anaemia. 
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AETIOLOGY OF IRON DEFICIENCY 
 
 In developing countries such as ours, a multitude of factors ranging from 
malnutrition, malabsorption, parasitic infestations, phytate rich diets, lack of 
motivation to seek medical help, early marriages, teenage pregnancies, or multiple 
consecutive pregnancies may be responsible for causing iron deficiency anaemia. 
An iron deficient state may be borne out of inadequate intake, insufficient 
absorption, increased utilization or excessive loss from the body.[1] 
 Certain food faddisms that are inherently low in iron content lead to 
decreased iron intake. Diets rich in iron such as dates, green leafy vegetables and 
meat should be encouraged. 
 A pregnant women may require up to 1000 mg of additional iron to sustain a 
healthy pregnancy.[27] An iron deficit may arise in growing children and pregnant 
women if the increase in iron demand is not met by an increased intake of iron. An 
increased iron demand is also observed following administration of erythropoiesis 
stimulating agents such as erythropoietin in patients with chronic kidney disease. 
 There could be an excess loss of iron from the body by way of insidious, 
traumatic bleeding or menorrhagia where iron is lost to the outside world along with 
haemoglobin in the blood. Any cause of acute or chronic blood loss may result in 
iron deficiency. Adults lose about 1 mg of iron per day that could rise up to 10 mg 
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per day in a normally menstruating woman.[1] Frequent blood donations could 
precipitate an iron deficient state as there is a loss of 500 mg of iron per donation. 
Therapeutic phlebotomy that is undertaken in polycythaemia coupled with increased 
erythropoiesis may also result in an iron deficient state.[1]Chronic haemoglobinuria 
due to paroxysmal nocturnal haemoglobinuria or hemolysis due to mechanical heart 
valve may lead to excessive iron loss as well.[28, 29] 
 A vitamin A deficiency interferes with normal metabolism of iron and may 
be responsible for impaired iron absorption.[31] Decreased iron absorption can arise 
due to concomitant intestinal malabsorption syndromes such as inflammatory bowel 
diseases, celiac sprue or Whipple’s disease.[1] The absorption of iron from the small 
intestine is also affected following intestinal resective surgeries.[32]  
 Lastly, and one of the most often implicated, is a decreased absorption of 
iron by the body. This may occur due to inadequate intake per se or due to 
abnormalities in the iron absorption pathway. Though genetic reasons for defective 
absorption have been identified in animals, it is poorly defined in humans.[30] 
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CLINICAL FEATURES AND SYSTEMIC MANIFESTATIONS OF IRON 
DEFICIENCY ANAEMIA 
 The importance of iron in health is exemplified by the derangements that 
occur in its deficiency. Iron deficiency and its associated anaemia can cause 
decreased stamina, easy fatigability, impaired cognition, altered audio and visual 
perceptions, infertility, increased antenatal mortality and morbidity and delayed 
psychomotor developmental milestones.[1] 
 Due to its vital role in cellular respiration, iron deficiency can present as 
decreased stamina or easy fatigability. A study undertaken in peripheral health 
centres observed that in only 1 in 52 patients presenting with fatigue, is the cause of 
fatigue anaemia.[33] On the other hand, detection of pallor as a screening procedure 
to pick up anaemia has a positive likelihood ratio of 4.5.[1] 
Pregnancy 
 India contributes to 44% of the global maternal mortality rate. Pregnancy 
poses a unique situation where the increased demand for iron by the growing foetus, 
coupled with the 50% rise in plasma volume, precipitates dilutional anaemia 
associated with iron deficiency. 40% of perinatal maternal deaths and an increased 
incidence of premature delivery are associated with iron deficient pregnancies.[43] 
Increased prenatal, perinatal infant and maternal mortalities and morbidities are 
observed in iron deficient women so much so that the chances of a favourable 
pregnancy outcome is reduced by 30 to 45%. Abnormal implantation or defective 
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embryogenesis of heart, lung and brain have been observed to be associated with 
iron deficiency.[10] In addition the infants born to such women have less than half 
the normal reserve of iron.[43]  
Growth In Children 
 The incidence of febrile seizures and breath holding spells is increased in 
infants who have iron deficiency anaemia. The physical and cognitive development 
of children with iron deficiency anaemia is impaired.[10] The importance of iron in 
growth is evident from studies that show improved growth following iron 
supplementation in iron deficient children. The improvement depends on the age of 
development of iron deficiency, dietary factors and presence of concomitant 
diarrhoea. Children who develop impaired immunity due to iron deficiency anaemia 
are highly susceptible to infectious diseases.[37, 44] 
CNS and Behaviour 
 Experiments with iron deficient animals show altered neurotransmitters and 
behaviour that stress the importance of iron in normal brain function.[34] This has 
been observed in iron deficient humans as well who exhibit impaired cognitive 
performance and delayed psychomotor milestones in infants and children. An iron 
deficient brain results in diminished attention span, poor academic performance, 
depression, altered sleep patterns and reduced mental alertness. Electrophysiological 
measurements undertaken in children and adults document a neurological 
malfunction associated with iron deficiency. A Costa Rican study demonstrated that 
infants with moderate anaemia achieved lower IQ scores and poorer cognitive 
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performance on entry into school than children who were not anaemic in their 
infancy.[35] A study published in 1992 by Balin et al showed that adolescent girls 
on supplemental iron demonstrated increased ability to concentrate in school.[38] 
Hence it is imperative that iron deficiency anaemia is prevented amongst infants and 
children to ensure normal cognitive development in their early formative years. 
Cardiovascular System 
 The resting heart rate of an iron deficient individual is increased. The 
microcytic hypochromic anaemia associated with iron deficiency anaemia leads to 
reduced oxygen carrying capacity of the red blood cells which results in a 
hyperdynamic circulation provided by a tachycardic heart. This may precipitate heart 
failure in patients with impaired heart function as it overburdens the system. 
Reduced ventricular function is observed with a reduced pre ejection period to left 
ventricular ejection time ratio (PEP/LVET). This ratio is normalized within days of 
iron therapy even before a documented rise in haemoglobin. ST depression may be 
observed in a treadmill test which is reversible following adequate therapy.[23]  
Gastrointestinal Tract 
 The cells of the gastrointestinal tract are continuously proliferating and 
differentiating. Iron, which is essential for DNA synthesis and cellular 
differentiation, when deficient will affect the entire length of the GI tract. At the oral 
end, a patient may present with angular stomatitis, cheliosis or glossitis. The 
postcricoid oesophageal web found in patients with Plummer Vinson syndrome is 
responsible for sideropenic dysphagia. Atrophic gastritis and malabsorption 
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syndromes are found concomitantly with iron deficiency. In a study conducted by 
Mehta et al, 28% of patients with iron deficiency showed a reversal of 
malabsorption of D-xylose accompanied by a significant rise in haemoglobin 
following iron therapy.[23] This suggests that iron deficiency can also cause 
malabsorption and not necessarily always vice versa. 
 The compensatory increased absorption of iron in iron deficient patients who 
exhibit abnormal eating behaviours of pica may prove to be toxic due to the 
concomitant increase in absorption of cadmium and lead by DMT-1. Iron deficient 
children are particularly susceptible to lead poisoning by ingestion of chipped paints 
or inhalation of automobile fumes due to this.[23] 
Immunity 
 Iron deficient individuals show increased susceptibility and morbidity to 
infections. Increased incidences of furunculosis, candidiasis and upper respiratory 
tract infections have been noted. This may be attributed to the diminished 
antimicrobial power of leukocytes due to impaired myeloperoxidase and phagocytic 
actions. The failure of lymphocytic replication on mitogenic stimulation results in 
reduction in the number of cells responsible for cell mediated immunity. Children on 
dietary supplements of iron have been known to reduce susceptibility to infectious 
diseases.[23]  As microorganisms thrive in an iron rich environment, the high 
prevalence of iron deficiency anaemia in a developing nation such as ours may in 
fact prove to be a blessing in disguise.[42] 
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Musculoskeletal System  
 Easy fatigability and reduced exercise tolerance are common symptoms of 
iron deficiency anaemia. Studies conducted amongst agriculture workers in many 
countries such as Indonesia, India and Sri Lanka have demonstrated a linear 
relationship between iron deficiency and work capacity.[40] A rapid return to 
normal has been documented through iron supplementation.[41]  
 Diminished iron stores in myocytes and the decreased myoglobin that is 
observed in iron deficient states result in exercise intolerance. This is particularly 
notable in fast acting group of muscles. A study conducted by Mann S.K. et al. in 
Punjab, amongst iron deficient non-anaemic females showed improved endurance 
levels and physical performance following iron supplementation.[37,41] 
Endocrine System 
 Iron deficiency is associated with impaired synthesis and catabolism of 
thyroid hormones and catecholamines. This results in altered neurological and 
musculoskeletal functions with impaired temperature control. Iron deficient 
individuals have low tolerance to cold. [23] 
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Skin and Appendages 
 Koilonochyia or spoon shaped (concave) nails is a well-known manifestation 
of chronic iron deficiency though exposure to petroleum products, trauma, high 
altitude or genetic causes may also result in this deformity.[39] There have been 
reports of premature greying or loss of hair, alopecia, acne and folliculitis in patients 
with iron deficiency with or without associated anaemia.[23]  
Iron Deficiency and Drug Metabolism 
 The iron containing cytochrome p450 system, which is responsible for drug 
metabolism, may be affected in iron deficiency. This could lead to altered 
pharmacokinetics and pharmacodynamics of drugs. An altered creatinine clearance 
that sometimes accompanies iron deficiency could also alter metabolism of 
xenobiotics. Hence, altered absorption, increased cardiac output, redistribution of 
drugs and altered renal function may affect drug biotransformation.[23] 
DIFFERENTIAL DIAGNOSIS 
 The clinical symptomology of anaemia is observed in megaloblastic anaemia 
caused by deficiency of vitamin B-12 or folic acid. Nutritional deficiency of 
Vitamin A or Vitamin C may mimic iron deficiency anaemia. Hereditary defects in 
haemoglobin synthesis or haemolytic conditions such as Glucose-6-Phosphate 
dehydrogenase deficiency and thalassemia may present with microcytic 
hypochromic anaemia. Anaemia of chronic disease can be differentiated from iron 
deficiency anaemia by the presence of normal to increased ferritin stores. Lead 
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poisoning presents with microcytic hypochromic anaemia but can be differentiated 
from iron deficiency anaemia by its characteristic signs and symptoms. Sideroblastic 
anaemia which may arise due to genetic causes or as part of myelodysplastic 
syndromes presents with microcytic hypochromic ringed sideroblasts.[4] 
DIAGNOSIS OF IRON DEFICIENCY ANAEMIA 
 A patient exhibiting signs and symptoms of anaemia must be evaluated 
further for the presence of iron deficiency anaemia.  To establish a diagnosis of iron 
deficiency anaemia, the patient must show laboratory confirmed evidence for the 
presence of anaemia as well as decreased iron stores. The former may be established 
by assessment of haemoglobin, haematocrit, peripheral smear and red cell indices, 
while the latter may be confirmed by assessing the iron parameters.  
 Investigating the levels of bone marrow iron is considered the gold standard 
for diagnosing iron deficiency anaemia but this technique is invasive and extremely 
painful.[37] Less invasive blood tests that assess haematological and iron parameters 
are available to evaluate the iron status of an individual. 
Laboratory Diagnosis of Anaemia 
 The laboratory diagnosis of anaemia may be made based on results of 
haemoglobin, red cell indices and a peripheral smear, tests that are routinely 
prescribed for their sensitivity and cost-effectiveness.   
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Haemoglobin 
 Haemoglobin, the iron containing oxygen transporter found in blood can be 
measured by colorimetry. Venous samples that have been mixed well with EDTA to 
prevent clotting should be used for this assay. Haemoglobin gets converted to a 
coloured protein known as ‘cyanmethhaemoglobin’ whose intensity is measured by 
a colorimeter. Haemoglobin levels depend on various factors such as age, sex, 
parity, nutritional status and altitude of living. Normal haemoglobin levels are 14 to 
16 g/d in males and 12 to 14 g/dl in females.[26] A haemoglobin value less than 2 
Standard deviations from an age and sex matched population mean at the same 
altitude is suggestive of anaemia.[26]  
Haematocrit 
 Haematocrit or packed cell volume (PCV) is the volume of red blood cells 
found per litre of blood. The normal PCV of males in 40 to 54%, and females is 36 
to 48%. Like haemoglobin, PCV tends to vary with plasma volume. Hence a high 
PCV will be noted in a dehydrated patient whilst a low PCV will be noted in an 
antenatal woman. Either capillary blood or venous blood with EDTA added to it 
may be used for this analysis. The sample has to undergo centrifugation and the 
packed cell height divided by the plasma level height expressed as a percentage 
gives the packed cell volume. [49] 
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Peripheral Smear 
 Peripheral smear examinations of unclotted blood stained with Wright's stain 
provides clues to detect abnormalities in RBCs, WBCs and platelets. The size, 
colour and number of RBCs may be discerned by this cost-effective assessment of 
peripheral smear. Iron deficiency anaemia presents with a microcytic hypochromic 
picture. Thalassemia, sideroblastic anaemia and lead poisoning may also present 
with a similar picture. [37] 
Red Cell Indices 
 Red cell indices, first described by Wintrobe in 1929, are used to describe 
the size (mean corpuscular volume) and haemoglobin concentration within an RBC 
(Mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration). 
Red cell distribution width (RDW) or red cell morphological index is used to 
quantify the variation in sizes of the RBCs. The size wise distribution of the RBCs 
can be depicted by a histogram known as the Prince-Jones curve or the coefficient of 
variation may be expressed as a percentage. The normal RDW ranges from 11.5% to 
14.5% and is expected to increase in iron deficiency anaemia. The change in RDW 
is the first haematological change noted in the peripheral smear of an iron deficiency 
individual, even before the appearance of microcytic hypochromic RBCs.[49] 
 Mean corpuscular volume (MCV) Mean corpuscular haemoglobin (MCH) 
Mean corpuscular haemoglobin concentration (MCHC) are all calculated from 
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haemoglobin, haematocrit (PCV) and RBC count. Table 3 presents the normal 
values and the expected change in iron deficiency anaemia.[49] 
Table 3: Red Cell Indices  
Parameters Normal 
Iron Deficiency 
Anaemia 
Calculation 
MCV 87 ± 7 fl Decreased PCV/RBC count 
MCH 29 ± 2 pg/ cell Decreased Haemoglobin/RBC count 
MCHC 34 ± 2 g/dl Decreased Haemoglobin/PCV 
 
PCV = volume of packed cells per 1000 ml of blood; Haemoglobin = Haemoglobin in g per 
1000 ml of blood; RBC count = RBC count in millions per ml of blood 
 40% of individuals with iron deficiency will demonstrate a normocytic 
normochromic picture on peripheral smear analysis.[36] MCHC is considered to be 
a highly sensitive indicator for iron deficiency anaemia, though its value indicates 
the iron status of the body during the entire lifespan of the RBC (~120 days).[49] To 
obtain a recent assessment of the availability of iron for incorporation into new 
RBCs, the haemoglobin concentration in reticulocytes [CHr] is assayed. The CHr 
test compares favourably with TSAT and serum ferritin in predicting response to 
intravenous iron. [47] 
Reticulocyte Count 
 Anaemia is accompanied by chronic tissue hypoxia which results in reflex 
increase in erythropoietin release and erythropoiesis. This is evident by the presence 
of numerous reticulocytes in the peripheral smear. Reticulocytes are immature 
anucleate erythroid cells in the peripheral blood with remnant extra nuclear RNA 
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which makes them 8% larger and more convoluted than their mature counterparts. 
On examination of the peripheral smear using Wright’s stain, reticulocytes will 
exhibit a bluish hue due to its residual RNA content. A reticulocyte count is done by 
examining a stained preparation of peripheral smear and expressing as a percentage 
the number of reticulocytes among 1000 erythrocytes. Flow cytometry is a relatively 
newer modality to obtain the absolute reticulocyte count. In conditions such as iron 
deficiency anaemia, reticulocyte count is expected to increase as the marrow 
responds to treatment.[48,49] 
 The above findings are not specific to iron deficiency anaemia, as numerous 
conditions such as thalassemia, sideroblastic anaemia, haemolytic anaemia and lead 
poisoning may present with a haematological profile similar to that found in iron 
deficiency.[1] 
Laboratory Evidence of Iron Status of the Body 
 There are two ways of confirming that the microcytic hypochromic anaemia 
is due to iron deficiency. One is to give a therapeutic trial of oral iron therapy for 1 
to 2 months and noting at least a 1g/dl rise in haemoglobin or a 3% increase in 
haematocrit. [37] A definitive diagnosis of iron deficiency anaemia based solely on 
haemoglobin, haematocrit and red cell indices cannot be arrived due to the following 
reasons: 
1. Due to the surrogate nature of the red cell parameters, the actual body iron 
status cannot be discerned. 
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2.  A change in haemoglobin and haematocrit levels occurs only in the last few 
stages of iron deficiency and up to 40% of patients with iron deficiency may 
not show an alteration in their peripheral smear 
3. The only way to confirm an iron deficient state in an individual utilizing 
haematological parameters is by noting a change in their values following 
therapy. Such a therapeutic trial is not justified in patients who do not have 
iron deficiency anaemia.  
4. The haematological profile in iron deficiency anaemia may be present in 
other diseases as listed under the differential diagnosis.  
 Hence, in order to truly ascertain the iron status of the body, assessment of 
iron parameters must be made. The iron parameters include serum iron 
concentration, serum ferritin, transferrin saturation, total iron binding capacity, 
unsaturated iron binding capacity, soluble transferrin receptor and zinc 
protoporphyrin. The latter two tests have been in the experimental stage for the past 
two decades and are considered to reflect the iron stores of the bone marrow.  
Serum Iron Concentration 
 As iron has the potential to induce free radical damage by Fenton’s reaction, 
it is always found bound to transferrin in plasma. Less than 1% of serum iron exists 
in an unbound form.[6]  
 The normal serum iron concentration ranges from 65 to 165mg/dl. [55] The 
majority of iron is derived from the catabolism of senescent RBCs which is a 
dynamic process. The turnover time for iron bound to transferrin is high as iron is 
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constantly being shuttled from storage or absorptive sites to sites utilizing it. As 
plasma iron circulates only for 40 to 50 min, intra individual variations in serum iron 
concentrations of up to 15% are observed. A diurnal variation of 10 to 20% may also 
be noted as serum iron concentration decreases in late afternoon and evening.[49,50] 
Serum iron concentration is expected to increase following dietary absorption and 
decrease as a response to various interleukins during inflammation, infection or in 
case of anaemia of chronic disease. Hence, defining an iron deficit based solely on 
serum iron concentration levels may result in false positive and false negatives 
without providing information on the iron stores of the body.[36] 
Serum Ferritin 
 Although ferritin is a storage form of iron and is found mostly in tissues and 
macrophages, some ferritin escapes into plasma and its plasma level is found to have 
a direct correlation to the iron stores. Serum ferritin concentration is a measure of 
the iron stores of the body.  Serum ferritin concentration can be accurately measured 
using chemiluminescence or ELISA.  
 The normal ferritin level is 40-160mcg/l.[55] Day to day variations and intra 
individual variations are not as pronounced as for iron. Previously, iron deficiency 
anaemia was defined as serum ferritin concentration of < 12mcg/l in females and 
<15 mcg/l in males. However this was found to possess an inadequate sensitivity of 
only 25%. Hence the cut-off limit was raised to 30mcg/l for both males and females 
increasing the sensitivity to 92% and the specificity to 98%.[4] Due to its high 
sensitivity and specificity, this test has gained wide acceptance as a diagnostic test 
for iron deficiency anaemia. [37,51]  
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 Serum ferritin concentration can be utilized to differentiate iron deficiency 
anaemia from anaemia of chronic disease with the former showing reduced iron 
stores and the latter showing normal to increased iron stores. Apo ferritin is an acute 
phase reactant which may be elevated in certain infections and inflammatory 
conditions resulting in a falsely elevated ferritin level. However, after careful 
elimination of co-existing infection or inflammation, serum ferritin level is a reliable 
test to define the iron status of an individual, especially in developing countries.[37] 
Total Iron Binding Capacity (TIBC) 
 Transferrin, the iron transporter in plasma, is usually saturated to one-third 
its capacity. TIBC is a reliable method of discerning transferrin concentration where 
the total number of transferrin binding sites per unit volume of plasma is 
assayed.[47]  
 TIBC can be calculated as the sum of serum iron concentration and 
unsaturated iron binding capacity or assayed using end-point colorimetric analysis. 
In the latter method, excess iron is added to the sample to saturate transferrin 
followed by precipitation of unbound iron. The quantity of iron bound to transferrin 
is assayed to obtain its total iron binding capacity. Normal values range from 250 to 
370 mcg/dl.[36] It is a stable indicator of iron status as it does not change until iron 
stores are depleted.                   
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 Increased TIBC values are noted in iron deficiency anaemia, acute liver 
damage, progesterone birth control pills and in late pregnancy, while decreased 
TIBC is observed in hemochromatosis, hemosiderosis, hyperthyroidism, nephrotic 
syndrome, anaemia of chronic disease and thalassemia. 
Unsaturated Iron Binding Capacity (UIBC) 
 This is the fraction of iron that remains unbound to transferrin when excess 
iron is added to the plasma. It can be assayed using end point colorimetric analysis 
where excess iron added to the sample binds to transferrin and the unbound iron is 
made to react with a colouring reagent, the colour intensity of which will give the 
fraction of unbound iron. It can also be calculated from TIBC values and serum iron 
concentration as depicted in the formula below: 
 UIBC(mcg/dl)= TIBC(mcg/dl)-Sr.Iron(mcg/dl) 
 Normal values range from 155 to 355 mcg/dl. As the value depends on the 
plasma iron levels, day to day variation, diurnal variation within the same individual 
can be noted. An iron deficient individual will exhibit increased unsaturated iron 
binding capacity. [49,52] 
Transferrin Saturation (TSAT) 
 This is a calculated value obtained by dividing serum iron concentration by 
TIBC and expressing the value as a percentage. 
TSAT % = Serum iron concentration x 100 
 
       TIBC 
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 Normal TSAT values range from 20 to 50%. In Iron deficiency anaemia, 
TSAT values lie less than 20%. TSAT <15% is considered to be insufficient to meet 
the requirements for normal erythropoiesis.[47, 55] TSAT values greater than 
normal indicate iron overloaded diseases such as hemochromatosis. As TSAT is 
directly proportional to serum iron concentration, any variation in serum iron 
concentration will directly affect TSAT values. Hence one can expect to note diurnal 
and day to day intra individual variations in TSAT values.  
Assessing Iron Stores of the Bone Marrow 
 The absence of stainable iron in the bone marrow is considered to be the gold 
standard test in diagnosing iron deficiency anaemia. This test has the demerits of 
being a painfully invasive procedure and is also subject to subjective inferences. 
Hence a search for less invasive, objective tests led to the assay of soluble 
transferrin receptor and the zinc protoporphyrin/ haeme ratio analysis. The former 
value does not vary in anaemia of chronic disease and neither values are affected by 
the presence of inflammation.  
Soluble Transferrin Receptor Assay 
 In iron deficiency, the erythropoietic cells of the bone marrow exhibit an 
upregulation of transferrin receptors, some of which get detached and are detectable 
in the circulation. An increased sTfR is not specific to iron deficiency as it is noted 
in patients with increased erythroblastic activity and in patients on erythropoiesis 
stimulating agents (ESA). The sensitivity for this diagnostic measures lies at 70 to 
81% with a specificity of 59 to 71%. [47] The sTfR/Ferritin Index which is a ratio of 
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sTfR to log ferritin is found to possess increased specificity and sensitivity in 
diagnosing iron deficiency. There is little consensus on performing this test as more 
studies are required to assess its utility. 
Zinc Protoporphyrin Assay 
 The terminal step in haeme synthesis pathway is iron chelation by 
protoporphyrin catalysed by ferrochelatase. Both iron and zinc compete for the 
metal binding site on ferrochelatase. When iron levels are decreased, zinc binds to 
the ferrochelatase and gets incorporated into the haeme moiety. It was 
conceptualized in 1966, that zinc protoporphyrin could be studied to evaluate the 
iron stores of the body.  As zinc protoporphyrin is fluorescent, its presence even in 
low concentrations can be detected increasing the sensitivity of the test. This test 
serves as an indicator for the availability of iron for erythropoiesis. Zinc 
protoporphyrin to haeme ratio analysis is found to possess increased specificity and 
sensitivity in diagnosing iron deficiency anaemia.[53] 
NEWER DIAGNOSTIC METHODS UNDER RESEARCH 
 Tests such as reticulocyte haemoglobin, percentage hypochromic 
erythrocytes, hepcidin levels and non-transferrin bound iron (NTBI) are under 
evaluation as potential tests for assessment of iron status of the body. [36] 
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CURRENT MANAGEMENT OF IRON DEFICIENCY ANAEMIA 
 Once diagnosed, iron deficiency anaemia can be treated by exogenous iron 
supplementation. Iron levels can be restored by dietary supplements, administration 
of oral, intravenous or intramuscular iron or by blood transfusion in severe cases. 
However, the cause for iron deficiency has to be ascertained and treated as a 
mere replenishment of the iron stores may not suffice for long. An intrinsically 
hypoplastic marrow would fail to recover following iron supplementation and 
likewise the responsiveness of the marrow may be masked by continued blood loss. 
Response to therapy would depend on the severity of the iron deficiency, mode of 
treatment, patient compliance and comorbidities that may influence the 
pharmacokinetics and pharmacodynamics of the therapy chosen. In most instances, 
where the cause of iron deficiency anaemia is nutritional, therapeutic interventions 
prove beneficial to the patient. [55]   
Oral Iron 
 Ferrous sulphate taken orally is the treatment of choice in iron deficiency. 
The bioavailability of ferrous salts is thrice that of ferric salts. Ferrous salts are 
available as sulphate, gluconate, fumerate, succinate, aspartate or a polysaccharide-
iron complex. The effective dose of the ferrous salt would depend on its inherent 
iron content, though variability in bioavailability due to the nature of the salt has not 
been noted.[56] 
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 Ferrous sulphate is commercially available as a heptahydrated salt (FeSO4 • 
7H2O) and contains 20% iron. Ferrous fumerate is water soluble, stable and tasteless 
with an iron content of 35% while ferrous gluconate has an iron content of 12%.[55] 
 The recommended dose to treat iron deficiency anaemia is 2 to 3 mg/kg/day 
given in 3 divided doses for adults. Pregnant women who require additional iron to 
support their growing foetus would need 15 to 30 mg/day of iron. When the 
circumstances do not demand haste, 100 mg of elemental iron per day would be 
sufficient to treat the iron deficiency. [55] 
 Concurrent administration of iron with antacids reduces the bioavailability of 
iron. Attempts of enhancing the oral bioavailability of ferrous salts by surface acting 
agents, carbohydrates, inorganic salts, amino acids or ascorbate have resulted in a 
significant increase in side effects. The bioavailability of oral ferrous salts is 
increased by one-third to half when taken on an empty stomach but is associated 
with an increased incidence of upper gastrointestinal side effects. However, certain 
delayed release preparations exhibit greater efficacy compared to ferrous sulphate 
when taken along with meals. It is also advisable not to use preparations that have 
been combined with folic acid, vitamin B-12 or cobalt in order to avoid difficulties 
in interpreting patient’s response.  
 The efficacy of therapy measured by its hematopoietic effects depends on the 
initial severity of the deficiency. A patient with haemoglobin of 5g/dl would require 
about 2 months to achieve a rise to normal levels, while a patient with an initial 
haemoglobin of 10g/dl would only require half that time to achieve the same. Hence 
the duration of therapy depends on the baseline haematological and iron parameters. 
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The restoration of iron stores of the body would require many months of therapy. 
The rate of increase in iron stores decreases after 3-4 months of therapy. Patients 
with concomitant bleeds or inadequate diet would require prolonged treatment.[55] 
 The biggest drawback to oral iron therapy besides its variable bioavailability, 
is the presence of GI adverse effects such as nausea, diarrhoea, constipation, 
heartburn and epigastric discomfort.[57] At high doses, nausea and epigastric 
discomfort are more prevalent. This intolerance to oral iron is due to the amount of 
soluble iron in the upper GI tract and may also be due to psychological factors. The 
change in bowel habits is not that noticeable at higher doses and are probably due to 
the effect of iron on intestinal bacteria. 25% - 40 % of those treated with oral iron 
exhibit the above symptoms. The high incidence of adverse effects, poor adherence 
to the treatment regimen and variable bioavailability result in inadequate response to 
therapy.[55]  
 If no improvement in the iron status is noted after 3 to 4 months of therapy, a 
switch to alternative treatment modalities such as parenteral iron therapy is 
warranted.[55] 
Parenteral Iron Therapy 
 Parenteral iron administration is the preferred route of therapy in patients 
who have failed to respond to oral iron. Common indications include patients who 
have undergone gastrectomy, gastrojejunostomy and other surgeries of the small 
intestine. It is also indicated in patients exhibiting severe intolerance to oral therapy 
and routinely prescribed for patients on erythropoietin.  
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 Parenteral iron formulations consist of an iron core encapsulated by a 
stabilizing carbohydrate shell which ensures release of iron within the cells of the 
reticuloendothelial system with minimal side effects. The current parenteral iron 
formulations available are iron dextran, sodium ferric gluconate, iron sucrose and 
ferumoxytol.[58,59] 
Iron Dextran 
 Iron dextran is a colloidal solution of ferric oxyhydroxide complexed with 
polymerized dextran and contains 50 mg/ml of colloidal iron. The use of low 
molecular weight dextran is preferred over high molecular weight dextran due to 
lesser toxicity associated with the former.  Iron dextran is indicated in any patient 
with documented iron deficiency not responding to oral iron. It may be administered 
as a total dose infusion, injected intravenously or intramuscularly. Both 
intramuscular and intravenous routes of administration must be preceded by a test 
dose of 0.5 ml. When total dose infusion is administered in a weekly spaced manner, 
test doses should precede each dose. The patient should be observed for one hour 
following the test dose for signs of immediate anaphylaxis, vascular instability, 
respiratory distress, hypotension, tachycardia, chest pain and back pain, any 
presence of which precludes further treatment with iron dextran. Fever, malaise, 
lymphadenopathy, arthralgia and urticarial reactions can occur days to weeks 
following therapy with iron dextran in patients with concomitant connective tissue 
disorders such as rheumatoid arthritis.[55]    
 When a dose of less than 500 mg is given intravenously, iron dextran 
complex has a t-half of 6 hours. At a dose of more than 1 g, the reticuloendothelial 
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clearance of 10 to 20 mg/hour results in brownish discoloration of the plasma with 
elevated levels of serum iron for a period of 1 to 2 weeks. Intramuscular iron dextran 
is to be administered as a dose of 0.5 to 2 ml using Z-technique over the upper 
quadrant of the gluteal region. There are concerns of local reactions at injection site 
and possible malignant changes associated with the intramuscular route. The 
intramuscular route is less reliable than the intravenous route, as in the former, iron 
has to be mobilized by the reticuloendothelial cells of the lymphatics before being 
released from the dextran complex.[58] 
Sodium Ferric Gluconate 
 Sodium ferric gluconate has a molecular size of ~29,500 Da and is 
administered at a dose of 62.5 to 125 mg intravenously. Unlike iron dextran, iron 
from ferric gluconate is directly delivered to transferrin within 24 hours. Sodium 
ferric gluconate has a lower incidence of anaphylaxis compared to iron dextran and 
is the preferred form of parenteral iron therapy. In patients on dialysis, sodium ferric 
gluconate ensures a transferrin saturation of 100%.[58] 
Iron Sucrose 
 Iron sucrose is a complex of polynuclear ferric hydroxide in sucrose that is 
pharmacokinetically similar to iron dextran. Its adverse effect profile is similar to 
ferric gluconate although one study has warned of additional potential renal injury in 
the form of tubulointerstitial damage following repeated use.  
 Iron sucrose and ferric gluconate have been FDA approved for patients with 
Chronic Kidney Disease (CKD) though wider applications are being sought. These 
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second generation iron formulations have to be administered at a lower dose to 
prevent dose related hypotension. They are associated with a lower incidence of 
adverse effects in comparison to the first generation iron dextran. [59] 
Ferumoxytol 
 Ferumoxytol is a newer intravenous semisynthetic preparation. It is a super 
magnetic iron oxide nanoparticle coated with carbohydrate. It is administered as 
fixed dose combinations in the treatment of anaemia due to chronic kidney disease. 
It can be given over 5 minutes and supplies 510 mg of iron per infusion. Rat paw 
oedema tests have demonstrated its low immunogenicity. It may, however, be 
associated with transient hypotension.[59] 
Blood Transfusion 
 Blood transfusion is reserved for seriously ill patients who need a rapid 
correction of their iron status. Though there are guidelines indicating cut-off 
haemoglobin levels for blood transfusion in severe anaemia, clinical factors and 
availability of blood also have to be considered. Transfusion of packed cell is 
preferred over whole blood in order to avoid volume overload. [1] 
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NEED FOR ALTERNATIVE TREATMENT FOR IRON DEFICIENCY 
 Both oral and parenteral iron are fraught with accompanying adverse drug 
reactions. While the oral route presents with mild tolerable side effects in a greater 
percentage of users (up to 40%), fatal anaphylaxis has been noted with the parenteral 
route in up to 0.7% of the users. Parenteral iron therapy is associated with adverse 
drug reactions such as bradycardia, chest pain, hypotension or hypertension, nausea, 
vomiting, diarrhoea, abdominal pain, headache, fever, allergic reactions, pruritus, 
malaise, arthralgias, myalgias, and back pain.[58] 35% of patients receiving iron 
sucrose exhibit mild adverse effects such as headache, nausea and diarrhoea, while 
iron dextran users complain of phlebitis when concentrated solutions are given over 
a prolonged period of time. Due to the high risk of anaphylaxis in parenteral iron 
therapy or transfusion reactions following blood transfusion, oral iron is the 
treatment of choice for mild to moderate anaemia. However, even this modality of 
treatment is not very patient friendly due to increased incidence of mild tolerable 
adverse drug reactions and poor oral bioavailability. Hence a need for an alternative 
treatment formulation exists. One such alternative form of therapy is lactoferrin, an 
iron binding glycoprotein.  
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LACTOFERRIN 
 Lactoferrin is an 80KDa glycoprotein belonging to the transferrin group of 
proteins. It was discovered in 1939 by Sorensen and Sorensen who first isolated it as 
‘red protein’ from bovine milk.  In 1960, it was found to be the main iron binding 
protein in human milk by three independent laboratories (Groves, 1960; Johanson, 
1960; Montreuil et al., 1960). Lactoferrin was found to exhibit 60% homology to 
transferrin. As this iron containing protein was extracted from milk and showed 
remarkable similarity to transferrin, it was named lactotransferrin and later renamed 
as lactoferrin.[5] 
 Lactoferrin has been subsequently found in the secretions of exocrine glands 
and in the granules of neutrophils. Over the years, since its discovery, it has been 
isolated, purified, and its chemical characteristics and structure been elucidated by 
various laboratories. The immunological, antibacterial, antiviral, and anti-parasitic 
activities of lactoferrin and its role in cell proliferation and differentiation have been 
extensively studied.  
 However, there is a dearth of studies defining its role in iron metabolism, 
especially in humans. Three European studies have shed some light on this subject 
and have suggested a plausible role for lactoferrin in the treatment of iron deficiency 
anaemia.[77,78,83]  
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Structure of Lactoferrin 
 The molecular structure of lactoferrin was elucidated in 1984. Lactoferrin 
consists of a single polypeptide chain of 703 amino acids, whose C – (carboxy) and 
N – (amino) terminal regions have been folded into two globular lobes that are 
connected by α-helix. Each lobe consists of two domains known as C1, C2, N1, and 
N2. The domains create an iron binding site on each lobe. [60] 
 
Figure 3: Richardson Ribbon Diagram of Lactoferrin. [61] 
Isoforms of Lactoferrin 
 There are three different isoforms of lactoferrin that have been isolated -- 
lactoferrin-α, lactoferrin-β and lactoferrin-γ. Only lactoferrin-α is capable of binding 
iron. Lactoferrin-β and lactoferrin-γ demonstrate ribonuclease activity which may 
play a role in its antimicrobial action.[5]  
Fe
3+
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 Compared to transferrin, lactoferrin exhibits double the ability to bind iron. 
Each lactoferrin can bind two ferric ions. Based on the level of saturation in 
lactoferrin, it may exist in three forms. Apolactoferrin is its iron free form. The 
monoferric form carries one ferric ion while hololactoferrin binds two Fe3+ ions. The 
tertiary structure of iron-free lactoferrin is different from the iron laden forms. More 
recent studies suggest that lactoferrin fluctuates between the apolactoferritin form 
and the hololactoferrin form, but prevails in the former. [5] Lactoferrin, unlike 
transferrin, is a highly basic protein, which may be responsible for the preservation 
of its iron binding properties even in the acidic milieu of inflammatory loci. 
Iron Binding Properties of Lactoferrin 
 The iron-lactoferrin bond is always associated with the concurrent binding of 
carbonate ion to the arginine residue of lactoferrin.[Fig.3] The histidine, tyrosine and 
aspartic acid residues of lactoferrin are important for its iron binding properties.[5]  
 
Figure 4: Iron Binding Sites of Lactoferrin [61]  
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 Lactoferrin shows remarkable resistance to proteolytic degradation by 
trypsin and trypsin-like enzymes, the level of resistance being proportional to the 
degree of iron saturation. A low saturation of 10% may be responsible for its 
resistance to degradation even at a low pH of 4. Glycosylation at different sites on 
the molecule confers additional resistance to degradation. The most common 
glycosylating saccharide is mannose. Hexoses account for 3% of the glycosylation 
while hexosamines account for 1%.[5]  
 Lactoferrin is also capable of binding other ions such as  Al3+, Ga3+, Mn3+, 
Co3+, Cu2+, Zn2+, oxalates and carboxylates albeit with a lower affinity. In addition 
to ions, lactoferrin can also bind to lipopolysaccharides, heparin, 
glycosaminoglycans and DNA.[5] 
Sources of Lactoferrin 
 Lactoferrin can be detected at the 2 cell stage of an embryo up until 
implantation. It is undetectable from then on till halfway through gestation. It is later 
detected in the neutrophil and epithelia of foetal reproductive and digestive 
systems.[5] 
 In adults, neutrophils are an important source of lactoferrin, where it is found 
mostly in the secondary granules. Due to its immunological functions, lactoferrin is 
found in most mucosal secretions such as uterine fluid, vaginal secretion, seminal 
fluid, saliva, bile, pancreatic juice, small intestinal secretions, nasal secretions, and 
tears.[63] It is also expressed and secreted throughout the collecting tubules of the 
kidney though its level in urine is quite low.[5] 
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 The blood or plasma concentration of lactoferrin is negligible (0.02 µg/ml to  
1.52 µg/ml) and varies based on age, gender, gestational age, stage of menstrual 
cycle, presence of infection, inflammation, tumour growth and extent of iron intake 
though the existing data pooled from different studies are incongruent.[5,64]  
 The highest concentration  of lactoferrin is found in colostrum (7g/dl) 
followed by milk (1g/dl) where it is believed to be a major source of iron for 
infants.[63] Lactoferrin is purified and isolated from human or cow’s milk though in 
the recent years recombinant lactoferrin is available. Human milk contains more 
lactoferrin but iron extraction from bovine lactoferrin is higher.[5] 
Regulation of Lactoferrin Synthesis 
 The regulation of lactoferrin synthesis depends on the type of cell producing 
it. Lactoferrin synthesized by the mammary glands is controlled by prolactin. Its 
production in reproductive tissues is controlled by oestrogens and epidermal growth 
factor. [5] The hormonal effects on lactoferrin concentration is further evident by its 
increased concentration during the proliferative stage of the menstrual cycle. Its 
concentration also changes during pregnancy with a progressive rise up to the 29th 
week after which it plateaus. This rise is attributed to the increased synthesis by the 
endometrium and the mammary glands as well as to the leucocytosis that 
accompanies pregnancy with increased concentration in the neutrophils.[5] 
 In neutrophils, the production of lactoferrin depends on the stage of 
maturation with a freeze on synthesis in mature neutrophils. It is synthesized during 
the differentiation of promyelocyte to myelocyte and is stored for later use in 
secondary granules. Exocrine glands continuously produce and secrete lactoferrin. 
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Neutrophil-derived lactoferrin differs from lactoferrin derived from milk, in lacking 
the terminal fucose residues in its glycan chains.[63]  
Lactoferrin Receptors 
 Lactoferrin receptors, typical for each cell type, have been found on the 
surface of hepatocytes, mucosal epithelial cells, fibroblasts and leucocytes including 
macrophages. Specific lactoferrin-binding proteins have been found in the intestinal 
microvilli of rabbit, mouse, and rhesus monkey suggesting a role for lactoferrin in 
iron absorption. These proteins vary in their molecular weight and their binding 
characteristics.  
 The receptor for lactoferrin found in the intestine is known as intelectin-1 
(ITLN-1). It is a calcium dependent galactofranose specific lectin (38 Kilo Daltons) 
encoded by the ITLN-1 gene. ITLN-1 exists as a soluble form or is found bound to 
the membrane of small intestinal brush border cells. The latter form of ITLN-1 is 
primarily responsible for mediating lactoferrin uptake by enterocytes. It is inserted 
through a glycosylphosphatidylinositol anchor or attached to glycolipid enriched 
lipid raft microdomains through its lectin activity.[65] A Japanese study conducted 
by Kouichirou Shin et al. in 2008, demonstrated the ability of human ITLN-1 to bind 
bovine lactoferrin suggesting the lack of species specificity for the receptor.[66] 
90% of the lactoferrin that is bound to its specific receptor on enterocytes, is 
degraded with the release of ferric ions. Decreased intracellular iron may result in 
increased expression of ITLN-1 facilitating an increased absorption of lactoferrin 
bound iron.[65] The mechanism of how ITLN-1 mediates iron uptake from 
lactoferrin is still unknown. [Figure 5.] 
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Figure 5 :Uptake of Iron-lactoferrin[45] 
 More than 60% of lactoferrin has been demonstrated to be absorbed by the 
adult human intestine. A study conducted in 2001 by Freddy J. Troost et al. in 
Netherlands demonstrated that lactoferrin is resistant to degradation by gastric 
juices.[46] Lactoferrin is metabolized and eliminated by two main mechanisms; one 
involving receptor mediated endocytosis by phagocytic cells, the other being a direct 
uptake by the liver. The phagocytic cells such as macrophages and monocytes 
subsequently transfer the iron content of lactoferrin to ferritin. The kidneys may play 
a role in the elimination of lactoferrin as traces of lactoferrin and its fragments of 
maternal origin have been detected in the urine of breast fed infants.[5] 
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Actions Of Lactoferrin 
 Lactoferrin is found to play versatile roles in iron absorption, immunity, 
inflammation, tumour growth, myelin genesis and enzymatic activities as discussed 
below. 
Lactoferin in Iron Homeostasis 
 Lactoferrin, due to its structural resemblance to transferrin has been 
implicated in influencing iron homeostasis. This idea came into existence when 
infants fed exclusively on breast milk (iron content 0.2 to 0.7 mg/l ) failed to 
demonstrate iron deficiency whereas infants fed on formula feeds needed to be 
supplemented with iron in order to prevent iron deficiency. Although the iron 
content of breast milk is low, its bioavailabilty is high. This, coupled with the 
abundant concentration of lactoferrin in breast milk may be responsible for 
preventing iron deficiency in breast fed infants. Urinary iron concentrations in 
neonates was found to be corresponding to lactoferrin concentrations in mothers’ 
milk further proving the uptake of lactoferrin by neonates.[64]  
 The notion that lactoferrin was involved in the absorption of iron was further 
strengthened by the evidence of receptors specific for lactoferrin on human intestine 
as established by Cox et al. in 1979.[67] It has been shown that lactoferrin receptors 
transport iron across the intestinal brush border and facilitate iron accumulation in 
brush border membrane vesicles.[64] Caco-2 cell lines transfected with lactoferrin 
receptor have demonstrated an increase by 1.7 to 3.4 times of lactoferrin absorption 
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compared to mock transfected cells  highlighting the unique receptor mediated 
uptake of iron. [65]   
 An animal experiment conducted by Kawakami H. et al. in Japan, comparing 
the efficacy of lactoferrin with ferrous sulphate in improving haematological 
parameters in iron deficient rats, demonstrated an improvement of parameters in the 
lactoferrin group.[69] An American study conducted by P.P.Ward et al. involving 
lactoferrin gene knock out mice failed to demonstrate a decrease in iron absorption. 
[68] Thus the role of lactoferrin in iron absorption has been equally refuted and 
proved by independent scientists which has led to considerable debates. 
Antimicrobial Effects of Lactoferrin 
 Lactoferrin exhibits a wide spectrum of antimicrobial actions as 
demonstrated by numerous studies. The antimicrobial effects of lactoferrin have 
been attributed to its iron binding property, where the iron required for the microbial 
survival has been sequestered by lactoferrin. Another mechanism proposed for its 
antimicrobial actions is the prevention of biofilm formation following iron 
sequestration. Receptors for N-terminal region of lactoferrin on some gram negative 
bacteria result in their cell membrane disruption. In gram positive organisms, the 
positively charged lactoferrin interacts with the negatively charged lipid layer 
altering the membrane permeability resulting in the bactericidal effect of 
lactoferrin.[5] 
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 The bactericidal activity of lactoferrin is also evident in the secondary 
granules of neutrophils where it acts as a source of iron generating free radicals that 
kill the microbes. Lactoferricin, a peptide degradation product of lactoferrin is 
considered to possess greater bactericidal activity than lactoferrin.[70] 
 Anti-viral properties of lactoferrin is evident by its binding to 
glycosaminoglycans of cell membranes which prevents the entry of  viruses such as 
herpes simplex virus and cytomegalovirus  and truncates the infection at an earlier 
stage.[71] Lactoferrin has also demonstrated anti-parasitic actions against 
trichomonas spp, toxoplasma gondii and pneumocyctis carinii.[72] 
Role of Lactoferrin in Immunity and Host defence 
 Lactoferrin is known to increase proliferation, differentiation and activation 
of the cells of the immune system. It has been shown that a deficiency of lactoferrin 
is associated with recurrent infections. This may be due to the lack of its actions in 
neutrophils. Lactoferrin concentrations have been noted to rise by 1000 fold in 
sepsis. Lactoferrin is also believed to exhibit anti-inflammatory properties. 
Lactoferrin is known to decrease pro-inflammatory cytokines such as tumour 
necrosis factor (TNFα), IL-1β and IL-6. [73] Thus the immunomodulatory 
properties of lactoferrin may prevent inflammatory damage to tissues. 
Antineoplastic Actions of Lactoferrin 
 Lactoferrin is believed to possess antineoplastic actions. This has been 
demonstrated in animal studies with chemically induced tumours where it has been 
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reported to inhibit development of metastasis in mice. Lactoferrin mediated 
increased cytotoxicity of NK cells has been implicated in its antineoplastic effects in 
epithelial and breast cancers. Low concentrations of lactoferrin have been shown to 
stimulate the lysis of tumour cells. The anti-tumour property of lactoferrin may also 
be attributed to its induction of apoptosis, though the exact mechanism is yet to be 
elucidated.[74] 
Lactoferrin as a Growth Factor 
 Lactoferrin has been implicated in myelopoisis, osteoblast proliferation and 
lymphocyte proliferation. It has been shown to increase proliferation of rat intestinal 
crypt cells. Lactoferrin, as a source of iron, facilitates DNA proliferation. It is 
believed to increase levels of BFU-E and GM-CSF and hence favour myelopoisis 
and erythropoiesis. Its role in myelopoisis is peppered with discrepancies though 
reports have failed to demonstrate any inhibitory effect of lactoferrin on 
myelopoisis.[75] 
 The action of lactoferrin on osteoblasts and chondrocytes could potentially 
result in its utility in treating diseases such as osteoporosis. Lactoferrin has 
demonstrated inhibition of osteoclastogenesis though no effect on bone resorption 
by mature osteoclasts has been noted. This effect may be due to its inhibition of 
osteolysis promoting cytokines such as TNFα or IL-1β. [5] 
Enzymatic Action of Lactoferrin 
 Lactoferrin possess structural moieties similar to ribonuclease A and has 
demonstrated ribonuclease activity. It is believed to be responsible for the DNase 
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and RNase activity in human milk. In addition, in vitro studies have demonstrated 
phosphatase and maltoligosaccharide hydrolysis activity. [5] 
Preparation of Lactoferrin Available 
 Lactoferrin is available as lactoferrin fortified bovine colostrum (Laktrum) in 
India.[Figure 6.] Each gram of Laktrum contains 10mg of lactoferrin in addition to 
50 mg of bovine colostrum. Bovine colostrum by itself contains 0.8 mg of bovine 
lactoferrin per gram of colostrum. 1 mg of bovine lactoferrin can bind approximately 
1.4 mg of iron.[62] Bovine colostrum of laktrum is harvested from Biopole Belgian 
cows within 24 hours and is processed by freeze drying thereby ensuring greater 
stability of the product. Bovine colostrum also contains 15 mg/g of 
immunoglobulins and growth factors such as Epithelial Growth Factor, Fibroblast 
Growth Factor, Platelet Derived Growth Factor, Transforming Growth Factor and 
Insulin Growth Factor 1 and 2.[76] In addition the product also contains mineral and 
vitamins in varied concentrations. The excipient added is colloidal silicon dioxide 
along with sucrose. This product has been in the market for its immunomodulatory 
and proliferative properties.   
 
Figure 6: Laktrum 
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Proposed Mechanism of Action of Lactoferrin in Anaemia 
 The mechanism of how lactoferrin improves anaemia has not been clearly 
defined. The possible mechanisms are as follows 
1. Lactoferrin may act as a source of iron as each holo-lactoferrin 
molecule contains two ferric ions which can be absorbed via the ITLN-
1 receptors present on enterocytes.[67] 
2. Lactoferrin may help sequester dietary iron by binding to iron in food 
and facilitating its uptake by enterocytes via the ITLN-1 receptor.[67] 
This would be particularly useful in individuals with reduced dietary 
iron absorption due to defective DMT-1/HCP-1 ferroportin pathway.  
3. Lactoferrin has been demonstrated to decrease IL-6 levels. Decreased 
IL-6 levels result in decreased synthesis of hepcidin, which facilitates 
increased expression of ferroportin on the basolateral membrane of the 
enterocytes thereby increasing iron absorption.[77] 
4. Lactoferrin is postulated to regulate levels of GM-CSF and BFU-E 
which in turn could influence myelogenisis and erythropoiesis. 
However, this action of lactoferrin is debatable due to discrepancies 
reported by numerous studies.[75] 
 In addition, there could be other hitherto unknown mechanisms of how 
lactoferrin improves haematological profiles in iron deficiency anaemia. Due to its 
iron binding properties, lactoferrin can be explored as an alternative form of therapy 
for iron deficiency. Hence a study was designed to assess the efficacy of lactoferrin 
fortified bovine colostrum in treating iron deficiency anaemia in Indian women. 
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AIM AND OBJECTIVE 
 
 
Aim  
 To compare the efficacy of oral lactoferrin fortified bovine colostrum (as a 
single agent and in combination with ferrous sulphate) with oral ferrous sulphate in 
treating iron deficiency anaemia. 
Objective 
 To compare the efficacy of oral lactoferrin fortified bovine colostrum (as a 
single agent and in combination with ferrous sulphate) with oral ferrous sulphate in 
treating iron deficiency anaemia by measuring haemoglobin levels and iron 
parameters. 
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MATERIALS & METHODS 
 
 This was a prospective, randomized, active controlled, 3 armed parallel 
open-labelled comparative study conducted at Govt. Kilpauk Medical College and 
Hospital between June 2013 and July 2014. 
 The study procedure required screening for patients with iron deficiency 
anaemia who satisfy the inclusion criteria, their subsequent recruitment, 
randomization and grouping, followed by baseline investigations. This was followed 
by a 30 day treatment regimen and analysis of post therapy investigations which 
assessed the efficacy of the treatment given.  
 The Institute Ethical Committee clearance was obtained prior to 
commencement of the study. The conduct of the study was along the guidelines laid 
down by ICMR on the conduct of biomedical research. 
Sample Size  
 Results from a previous study conducted on Italian pregnant women was 
used to calculate sample size as there are no equivalent Indian studies.[77] A two 
sided t-test was employed to detect superiority of lactoferrin fortified bovine 
colostrum over ferrous sulphate. A minimum sample size of 12 per group was 
required to have a 90% chance (alpha error of 0.05) of detecting an increase in 
haemoglobin level to 11.5 g/dl (S.D of 0.6 g/dl) in the ferrous sulphate group and 
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12.7g/dl (S.D of 0.9 g/dl) in the experimental group.  On adjustment for non-
compliance in the ferrous sulphate arm to 40%, a sample size of 68 was arrived at.  
Screening 
 Four medical camps were organized by the principal investigator amongst 
nursing students belonging to the School of Nursing, Govt. Kilpauk Medical College 
and Hospital, Chennai. Nursing students were chosen as a cohort in order to 
minimize confounding factors with the added advantage of age-matched 
counterparts in each group.  
 During the medical camp, conjunctival pallor was assessed clinically. Those 
found to be pale were advised to get their haemoglobin and peripheral smear 
assessed. 
Recruitment 
 Students fulfilling the inclusion criteria were briefed on the study. Written 
informed consent was obtained from those willing to participate in the study.  A 
detailed history and clinical examination was performed on the participants. Venous 
blood was drawn for baseline assessment of iron parameters and other routine tests. 
Grouping 
 The study design envisaged a randomization of the study population into 3 
arms. The control arm received oral Ferrous Sulphate 333mg (100mg elemental 
iron) once daily. The study arm received oral Lactoferrin Fortified Bovine 
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Colostrum 2g once daily. The third arm received both Ferrous Sulphate and 
Lactoferrin Fortified Bovine Colostrum. 
Table 4: Grouping of Study Participants 
Group I Group II Group III  
n=25 n=25 n=18 
Oral Ferrous sulphate Oral Lactoferrin Fortified 
Bovine Colostrum  
Oral Ferrous sulphate and 
Lactoferrin Fortified 
Bovine Colostrum  
 
Drugs Used in the Study and Their Sources 
1. Tab. Ferrous Sulphate 333 mg (100 mg of elemental iron) once daily to be 
taken on empty stomach. This drug was sourced from Govt. Kilpauk Medical 
College and Hospital, Chennai. 
2. Oral Laktrum 2g once daily to be taken on an empty stomach. This  
nutraceutical was supplied by ‘Tablets India’, Chennai. 
 Both supplements were administered orally for a period of 30 days.  
Lactoferrin Fortified Bovine Colostrum was supplied as a powder and had to be 
reconstituted in 200 ml of potable water before consumption. 
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Randomization 
 A simple randomization method was adopted using Microsoft Excel. 
Random numbers between 0 to 1 (up to 4 decimal points) were generated. The 
participant enrollment number was arranged numerically (1 to 68).A filter was 
applied to arrange the random numbers in the ascending order.  The first 25 numbers 
were assigned as controls (Group I – Ferrous Sulphate Arm). The next 25 numbers 
were assigned to the Test group (Group II – Lactoferrin Fortified Bovine Colostrum 
Arm) and the last 18 numbers were assigned to the group receiving both the test and 
the control supplements (Group III – Combination Therapy Arm). 
 The participant enrollment number was assigned in running number as and 
when a student was found suitable for recruitment into the study.   
Inclusion Criteria 
 A Student was considered suitable for the study if she satisfied the following 
inclusion criteria: 
a. Females above the age of 18 years. 
b. Presence of hypochromic microcytic anaemia. 
c. Haemoglobin level between 8 and 11 mg/dl. 
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Exclusion Criteria 
 Students with the following criteria were excluded from the study: 
a. Female patients under 18 years of age or Male patients. 
b. Non-microcytic hypochromic anaemia. 
c. Haemoglobin levels more than 11 mg/dl or less than 8 mg/dl.  
d. Known cases of anaemia due to secondary causes such as 
infections, neoplasms, genetic diseases, hypochlorhydria or 
renal disease 
e. Presence of inflammation or infection detectable by a raised 
ESR (associated with increased ferritin levels leading to false 
negatives). 
f. Patients on any medication that could interfere with iron 
absorption such as antacids/ PPIs. 
g. Patients on iron supplements or a history of recent 
supplementation (past 3 months). 
h. Patients having menorrhagia or a known source of bleeding 
(varices, ulcers etc.). 
i. Patients requiring blood transfusion or with recent history of 
blood transfusion. 
j. Seriously ill patients 
 Students who fit the inclusion criteria and were willing to participate in the 
study were recruited into the study. 
78 
 
Assessment of Participants 
 A clinical assessment was performed (as per annexure II) after obtaining a 
detailed history. The findings were duly noted in the case report forms (CRF). 
 8ml of venous blood was collected from the subject under strict aseptic 
precautions for routine investigations such as: 
 Complete Blood count (TC, DC, ESR, Haemoglobin)  
 Peripheral Smear 
Sr. Urea 
Sr. Creatinine 
Sr. Bilirubin 
SGOT/PT 
Assessment of Iron Status of the Participants 
 Sample for iron studies was aliquoted and made to rest for a minimum of one 
hour after which it was centrifuged at 3000 r.p.m for four minutes. The serum was 
separated and aliquoted into 3 separate eppendorfs after appropriate labelling. 
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 The eppendorf with the sera were stored in the deep freezer at -20 degrees 
centigrade for running the following tests at a later date: 
1. Sr. Iron 
2. Sr. Ferritin 
3. Total Iron binding capacity 
4. Sr. Transferrin Saturation (to be calculated from above)  
5. Unsaturated Iron Binding capacity ( to be calculated from above) 
I. Quantitative Estimation of Serum Iron 
 Serum iron concentration was measured by end-point colorimetric assay 
using FERROZINE (Spinereact Ref: 1001247, 1001248).  
Principle of the Test 
 Iron dissociated from transferrin by provision of an acidic medium and 
reduced to ferrous form by addition of ascorbic acid. This reduced iron forms a 
coloured complex in combination with ferrozine, the intensity of which is measured 
using colorimetric analysis and is indicative of serum iron concentration. 
 Colorimetric analysis has been a reliable, reproducible and sensitive method 
of assaying serum iron concentration over 20 years.  The specificity of the test was 
enhanced by blanking where every test samples is paired and reagent added to only 
one of the pairs.[Figure 7.] This method of blanking facilitates the measurement of 
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the baseline absorbance of the samples which can be subtracted from its paired 
reading to provide accurate serum iron concentration values. 
 
Figure 7: Blanking Procedure for Serum Iron Concentration Analysis 
Materials Required 
1. Ferrozine kit (1 No.) containing 
i. 100 mmol/L of acetate at pH 4.9 that acts as a buffer 
ii. Ascorbic acid ( 99.7%)  
iii. 40 mmol/L FerroZine color 
iv. 100 ug/dl of aqueous iron as standard   
2. Colorimeter measuring at 562 nm 
3. 100 mcl, 200mcl, 1000mcl micropipettes with disposable micropipette 
tips , test tubes 
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Procedure 
1.  Working reagent was prepared by adding one tube of ascorbic acid to one 
bottle of buffer and mixed gently to dissolve the contents.  
2.  The instrument was calibrated to read at 562 nm with a 1 cm cuvette light 
path at room temperature. Instrument was adjusted to zero with distilled 
water. 
3.  Test tubes were paired and labelled. A working reagent (WR) blank and 
standard were tested with every batch that is processed.    
4.  Reagents were added as presented below [Table 5.]: 
Table 5: Reagents Used In Serum Iron Assay 
Components WR Blank Standard Sample Blank Sample 
WR (ml) 1 1 1 1 
Ferrozine (drops) 1 1 - 1 
Distilled water (microliter) 200    
Standard (microliter)  200   
Sample (microliter)   200 200 
 
5. Contents of each test tube were allowed to mix and incubate for 10 min at 
room temperature 
6. The absorbance [A] of standard and sample against WR blank was 
measured using a colorimeter after calibration. 
7. The concentration of sample iron was calculated as follows: 
8. Serum Iron Concentration (mcg/dl) = [A] Sample – [A] Sample Blank X100 
[A] Standard 
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II. Quantitative Estimation of Serum Ferritin  
 Serum ferritin was assayed by an enzyme-immunoassay (EIA) validated for 
quantitative in-vitro determination of ferritin in human serum. 2 kits of 
PATHOZYME FERRITIN (Ref OD407) were procured for the same.  
Principle of the Test 
 The test is based on the general principle of an Enzyme linked immunoassay. 
Specific anti ferritin antibodies coated onto the micro titration wells, bind to ferritin 
in the test sera. A conjugate of a monoclonal anti-ferritin labelled with horseradish 
peroxidase enzyme is then made to bind to the ferritin. On addition of the substrate, 
a development of change in colour indicates the presence of ferritin. The intensity of 
the colour quantified by colorimetric analysis, translates to the concentration of 
ferritin in the test sera. 
Materials Required  
1. 100 mcl, 200mcl, 1000mcl micropipettes with disposable micropipette 
tips 
2. Absorbent paper 
3. Micro plate reader with a 450 nm filter 
4. Micro plate washer 
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5. 2 kits of PATHOZYME [R] FERRITIN (Ref OD407) with the 
following contents:  
i. 12x8x1 breakable wells coated with a specific antibody  
ii. 0.5 ml of 6 reference standards of 0ng/ml, 15ng/ml, 80ng/ml, 
250ng/ml, 500ng/ml and1000ng/ml of ferritin diluted in human 
serum 
iii. 11 ml of anti-ferritin Horse radish peroxidase conjugate 
iv. 11 ml of substrate solution 3,3’,5,5’ Tetra methyl benzidine in 
citrate buffer 
v. 11ml of dilute hydrochloric acid as stop solution  
Assay Procedure 
1. The kit components were all brought to room temperature of 20-25 
degree Celsius prior to the start of the assay and were mixed 
thoroughly by gentle inversion. 
2. The test sera were arranged and labelled in running numbers. 
3. 6 wells were designated for standardization per batch.  
4. 100 microliters of anti-ferritin was dispensed in each well carefully 
without touching the walls of the well.  
5. 20 micro litres of the standard and test sera were dispensed into the 
wells using a micro pipette. 
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6. 100 micro litres of horseradish peroxidase enzyme conjugate was 
instilled into all the wells. 
7. The three components were thoroughly mixed in their respective wells 
by gentle rotatory movements of the micro titre plate.  
8.  The plate was then allowed to incubate for 45 min at room 
temperature.  
9. The contents of the micro titre plate were then discarded and were 
placed in the micro plate washer which was programmed to instil 300 
micro litres per cycle and run for 5 cycles.  
10. The plate was removed from the washer and any residual water 
removed by sharply striking the plate onto absorbent blotting paper. 
11. 100 micro litres of the substrate was added to each well, mixed and 
allowed to incubate for 20 minutes. Care was taken not to expose the 
wells to direct sunlight. 
12. 100 micro litres of stop solution was added to each well to stop further 
reactions which was indicated by the change in colour from blue to 
yellow. 
13. The optical density of each well was read with using a micro plate 
reader with a 450 nm filter calibrated to a quadratic regression curve 
fit. 
 
85 
III. Quantitative Estimation Of Total Iron Binding Capacity (TIBC) 
 TIBC was measured by end point analysis by saturation- precipitation 
method. 2 kits of Spinereact TIBC (Ref: 1001241) were procured for the same. 
Principle of the Test 
 Serum transferrin is saturated with excess ferric ion and precipitation of 
unbound iron induced by the addition of magnesium carbonate. After centrifugation, 
the iron in the supernatant is measured using endpoint calorimetry method as 
described for serum iron assay.  
Materials 
1. TIBC kit containing  
a. 500 mcg/dl of iron solution 
b. Magnesium carbonate 
2. Ferrozine kit with contents as described for serum iron assay 
3. Colorimeter measuring at 562 nm 
4. 100 mcl, 200mcl, 1000mcl micropipettes with disposable micropipette 
tips , test tubes 
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Procedure 
1. Samples arranged in order were assigned running numbers and 
labelled. 
2. To 0.5 ml of sample, 1 ml of iron solution was added, mixed well and 
allowed to incubate at room temperature for 10 min. 
3. 3 spoonsful (~ 70 mg) of precipitating reagent were added to each tube, 
mixed well and allowed to incubate for 10 min at room temperature.  
4. The contents of the test tubes were then centrifuged for 15 minutes at 
3000 revolutions per minute 
5. The supernatant was collected carefully and iron content measured.  
6. TIBC was calculated as follows: 
 TIBC= Iron concentration in supernatant X 3 (dilution factor) 
 
Figure 8: Precipitation of Unbound Iron in TIBC Assay 
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IV. Calculation of Unsaturated Iron Binding Capacity 
 Unsaturated Iron Binding Capacity was calculated as follows: 
 UIBC (mcg/dl) =TIBC- Sr.Iron 
V. Calculation of Transferrin Saturation (TSAT) 
 Transferrin Saturation was calculated parameter as follows: 
 TSAT % = Serum iron concentration x 100 
 
STATISTICAL ANALYSIS 
 Statistical analysis was performed using SPSS version 17 software. 
Continuous variables were to be described as means along with their standard 
deviations while discrete variables were expressed as frequencies and percentages. 
Distributions for continuous variables were assessed for their linearity. Within each 
group, the mean change in haemoglobin and iron parameters from baseline to post-
therapy was assessed using student’s paired t-test. A one way ANOVA was 
employed to assess the significance of change in parameters between the three 
groups. A non-parametric Wilcoxon signed rank test was employed for the analysis 
of serum ferritin.  A descriptive analysis was undertaken for the analysis of Adverse 
Drug Reactions that occurred during the study period. 
 
TIBC 
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RESULTS 
 A total of 242 students were screened for the clinical presence of conjunctival 
pallor. A complete blood count and peripheral smear was undertaken on 84 students 
who were found to exhibit clinical pallor.[Figure 9] 16 of them did not fit the inclusion 
criteria and were excluded from the study. The 68 students recruited into the study were 
randomly allotted into three groups as depicted in Table 4.  
35%
65%
Prevalence of Anaemia
Presence of clinical pallor Absence of clincial pallor n=242
 
Figure 9: Pie Chart of Prevalence of Anaemia 
 Demographics 
 As per the inclusion criteria, all the participants of the study belonged to the 
female gender. The mean age of the study participants was found to be 19.15 ± 
0.685 years ranging from 18 to 21 years. There was no significant variation in age 
within group or between the three groups. 
Routine Investigations 
 The baseline and post-treatment values of TC, DC, ESR, SGOT, SGPT, Sr. 
Urea, Sr. Creatinine and Sr.Bilirubin were found to be normal in all the subjects.  
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Table 6: Group I (Ferrous Sulphate Arm) Descriptive Statistics 
Parameters Sample Minimum Maximum Mean S.D 
Haemoglobin (g/dl)  Baseline 8 11 9.5191 0.76271 
Haemoglobin (g/dl)  Post-therapy 7.8 12.5 10.1391 0.91135 
Sr. Ferritin (mcg/dl) Baseline 0.399 136.1 19.87175 25.50824 
Sr.Ferritin (mcg/dl)  Post-therapy 2.653 191.5 20.60839 27.60475 
Sr.Iron (mcg/dl)        Baseline 8.82 106.7 48.4379 22.42331 
Sr.Iron (mcg/dl)        Post-therapy 12.59 164.74 60.2364 23.24625 
Sr.TIBC (mcg/dl)        Baseline 321.78 694.35 511.1379 76.84376 
Sr.TIBC (mcg/dl)        Post-therapy 260.07 678.63 438.3676 72.13451 
Sr. UIBC (mcg/dl)      Baseline 236.12 649.46 462.7 81.11258 
Sr.UIBC (mcg/dl)     Post-therapy 157.46 613.75 378.1312 74.48859 
Sr.TSAT (%)                Baseline 1.75 19.13 9.9287 4.51106 
Sr. TSAT (%)               Post-therapy 2.77 25.15 10.7201 5.33559 
 
Table 7: Group I (Ferrous Sulphate Arm) Paired t-Test 
Change in Parameter Mean 
95% Confidence Interval 
p-Value 
Lower Upper 
∆ Haemoglobin 0.028 -0.12942 0.18542 0.717 
∆ Sr. Ferritin -0.71956 -5.3926131 3.9534931 0.753 
∆ Sr. Iron 1.544 -8.4068 11.4948 0.752 
∆ TIBC -16.8732 -48.86705 15.12065 0.287 
∆ UIBC -18.4172 -54.79935 17.96495 0.307 
∆ TSAT 0.79140 -1.47008 3.05289 0.477 
* p<0.05 is considered significant 
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Table 8:  Group II (Lactoferrin Fortified Bovine Colostrum Arm)  
Descriptive Statistics 
Parameters Sample Minimum Maximum Mean S.D 
Haemoglobin (g/dl)   Baseline 8 11 9.4784 0.83044 
Haemoglobin (g/dl)   Post-therapy 8 12.5 10.4072 1.08726 
Sr. Ferritin (mcg/dl)  Baseline 0.666 136.1 20.11496 28.36195 
Sr.Ferritin (mcg/dl)   Post-therapy 2.84 153.17 20.81648 30.84125 
Sr.Iron (mcg/dl)         Baseline 17.34 80.66 48.272 18.82853 
Sr.Iron (mcg/dl)         Post-therapy 16.94 164.74 66.7672 39.40832 
Sr.TIBC (mcg/dl)        Baseline 372.99 681.87 510.504 81.48118 
Sr.TIBC (mcg/dl)        Post-therapy 302.49 621.39 392.328 78.60037 
Sr. UIBC (mcg/dl)      Baseline 315.09 625.68 462.232 83.00612 
Sr.UIBC (mcg/dl)      Post-therapy 157.46 548.79 325.5608 93.00596 
Sr.TSAT (%)                Baseline 3.08 16.22 9.6780 3.95709 
Sr. TSAT (%)               Post-therapy 4.62 50.56 17.8374 11.50182 
 
Table 9: Group II (Lactoferrin Fortified Bovine Colostrum Arm) Paired t-Test 
Parameters Mean 
95% Confidence Interval 
p-Value 
Lower Upper 
∆ Haemoglobin* 0.9288 0.5634 1.2942 <0.01 
∆ Sr. Ferritin 0.701521 -4.6488118 6.0518534 0.789 
∆ Sr. Iron* 18.4952 4.40917 32.58123 0.012 
∆ TIBC* -118.176 -157.64586 -78.70614 <0.01 
∆ UIBC* -136.671 -185.53979 -87.80261 <0.01 
∆ TSAT*  8.15946 3.67436 12.64456  0.01 
* p<0.05 is considered significant 
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Table 10: Group III (Combination Therapy Arm) Descriptive Statistics 
Parameters Sample Minimum Maximum Mean S.D 
Haemoglobin (g/dl)  Baseline 8 11 9.0562 0.98791 
Haemoglobin (g/dl)  Post-therapy 8.1 11.5 10.1187 0.8916 
Sr. Ferritin (mcg/dl) Baseline 1.803 91.65 25.42547 27.98601 
Sr.Ferritin (mcg/dl)  Post-therapy 3.852 191.5 28.49009 46.87105 
Sr.Iron (mcg/dl)        Baseline 10.79 92.5 44.4869 23.69757 
Sr.Iron (mcg/dl)        Post-therapy 14.86 112.6 61.8444 26.74477 
Sr.TIBC (mcg/dl)        Baseline 321.78 686.7 492.8187 98.28453 
Sr.TIBC (mcg/dl)        Post-therapy 260.07 678.63 403.6556 101.6775 
Sr. UIBC (mcg/dl)      Baseline 236.12 649.46 448.3319 108.9829 
Sr.UIBC (mcg/dl)     Post-therapy 175.25 606.08 341.8113 110.5557 
Sr.TSAT (%)                Baseline 2.07 16.63 9.2842 5.20309 
Sr. TSAT (%)               Post-therapy 3.25 33.27 16.9779 8.55587 
* p<0.05 is considered significant  
Table 11: Group III (Combination Therapy Arm) Paired t-Test 
Parameters Mean 
95% Confidence Interval 
p-Value 
Lower Upper 
∆ Haemoglobin * 1.0625 0.52544 1.59956 0.001 
∆ Sr. Ferritin 3.064625 -11.9268783 18.0561283 0.669 
∆ Sr. Iron * 17.3575 4.50649 30.20851 0.011 
∆ TIBC* -89.1631 -153.66176 -24.66449 0.01 
∆ UIBC* -106.521 -173.23954 -39.80171 0.004 
∆ TSAT* 7.69367 3.66723 11.72011 0.01 
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Figure 10: Bar Diagram of Serum Haemoglobin 
Student’s paired t-test for Haemoglobin  
 Participants in Group I (Ferrous Sulphate Arm) showed a mean increase in 
haemoglobin of 0.028 g/dl which was not found to be statistically significant  
(p = 0.717). 
 Participants in Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
showed a significant increase in their haemoglobin levels post-therapy with a mean 
increase in haemoglobin of 0.9288 g/dl (p<0.001) 
 Participants in Group III (Combination Therapy Arm) also showed a 
significant increase in their haemoglobin levels post-therapy with a mean increase in 
haemoglobin of 1.0625 g/dl (p=0.001). 
ANOVA and Multiple Comparison Test Analysis of Haemoglobin 
 There was no significant difference in baseline values between the three 
groups.  However, a significant difference in the rise in haemoglobin values in 
Group II and III (p <0.001 and 0.001 respectively) was noted in comparison to 
Group I (p = 0.717). There was no significant difference in the rise in haemoglobin 
between Group II and Group III (p = 0.877). 
93 
 
Figure 11: Bar Diagram of Serum Ferritin 
Wilcoxon Signed-Rank Test for Serum Ferritin 
 It was found that ferritin followed a non-normal distribution. Hence a non-
parametric Wilcoxon signed-rank test was employed to analyse serum ferritin levels. 
 A Wilcoxon signed-rank test demonstrated a decrease in ferritin stores in 
participants of Group I (Ferrous Sulphate Arm) that was not found to be statistically 
significant (p = 0.420, z = 0.807). 
 Participants of Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
demonstrated an increase in ferritin levels post-therapy which was again found to be 
statistically insignificant (p = 0.819, z = 0.229). 
 Participants of Group III (Combination Arm) demonstrated an increase in 
ferritin levels post-therapy which was also found to be statistically insignificant (p = 
0.717, z = 0.362). 
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Figure 12: Bar Diagram of Serum Iron 
Student’s Paired t-test for Serum Iron Concentration 
 Participants in Group I (Ferrous Sulphate Arm) showed a mean increase in 
serum iron concentration of 1.544 mcg/dl which was not found to be statistically 
significant (p=0.752). 
 Participants in Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
showed a significant increase in their serum iron concentration values post-therapy 
with a mean increase in serum iron concentration of 18.4952 mcg/dl (p= 0.012). 
 Participants in Group III (Combination Therapy Arm) also showed a 
significant increase in their serum iron concentration values post-therapy with a 
mean increase in serum iron concentration of 17.3575 mcg/dl (p=0.011). 
ANOVA and Multiple Comparison Test Analysis of Serum Iron Concentration 
 There was no significant difference in baseline values of serum iron 
concentration between the three groups. There was no significant difference in the rise 
in serum iron concentration levels between the three groups (p = 0.095,0.198, 0.991). 
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Figure 13: Bar Diagram of TIBC 
Student’s paired t-test for Total Iron Binding Capacity (TIBC) 
 Participants in Group I (Ferrous Sulphate Arm) showed a mean decrease in 
TIBC of 16.8732 mcg/dl which was not found to be statistically significant  
(p= 0.287). 
 Participants in Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
showed a significant decrease in TIBC values post-therapy with a mean decrease in 
TIBC of 118.176 mcg/dl (p < 0.001). 
 Participants in Group III (Combination Therapy Arm) also showed a 
significant decrease in their TIBC values post-therapy with a mean decrease in TIBC 
of 89.16313 mcg/dl (p = 0.01). 
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ANOVA and Multiple Comparison Test Analysis of Total Iron Binding 
Capacity (TIBC) 
 There was no significant difference in baseline values of TIBC between the 
three groups. 
 Post-therapy TIBC values of Group II and III were significantly different 
from that of Group I (p<0.01, p = 0.01 respectively). There was no significant 
difference in the post-therapy TIBC values between Group II and III (p = 0.904). 
 When a difference in difference analysis was carried out, the fall in TIBC 
values of Group II were significantly more than that observed in Group I  
(p = 0.001).  
 There was no significant difference in change in TIBC values observed 
between Group I and III (p = 0.057) or between Group II and III (p= 0.616) 
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Figure 14: Bar Diagram of UIBC 
Student’s Paired t-test for Unsaturated Iron Binding Capacity (UIBC) 
 Participants in Group I (Ferrous Sulphate Arm) showed a mean decrease in 
UIBC of 18.4172 mcg/dl which was not found to be statistically significant  
(p = 0.307). 
 Participants in Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
showed a significant decrease in UIBC values post-therapy with a mean decrease in 
UIBC of 136.6712 mcg/dl (p <  0.001) 
 Participants in Group III (Combination Therapy Arm) also showed a 
significant decrease in their UIBC values post-therapy with a mean decrease in 
UIBC of 106.521mcg/dl (p = 0.004) 
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ANOVA and Multiple Comparison Test Analysis of Unsaturated Iron binding 
Capacity (UIBC) 
 There was no significant difference in baseline values of UIBC between the 
three groups. 
 Post-therapy the UIBC values of Group II and III were significantly different 
from that of Group I (p < 0.01, p = 0.01 respectively). There was no significant 
difference in the post-therapy UIBC values between Group II and III (p = 0.844) 
 When a difference in difference analysis was carried out, the fall in UIBC 
values of Group II and III were significantly more than that observed in Group I  
(p = 0.001,0.039 respectively)  
 There was no significant difference in change in UIBC values observed 
between Group II and III (p= 0.668) 
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Figure 15: Bar Diagram of TSAT 
Student’s paired t-test for Transferrin Saturation (TSAT) 
 Participants in Group I (Ferrous Sulphate Arm) showed a mean increase 
TSAT of 0.79140% which was not found to be statistically significant (p = 0.477). 
 Participants in Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
showed a significant increase in TSAT values post-therapy with a mean increase in 
TSAT of 8.15946% (p = 0.001). 
 Participants in Group III (Combination Therapy Arm)also showed a 
significant increase in their TSAT values post-therapy with a mean increase in 
TSAT of 7.69367% (p = 0.001). 
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ANOVA and Multiple Comparison Test Analysis of Transferrin Saturation 
(TSAT) 
 There was no significant difference in baseline values of TSAT between the 
three groups. 
 Post-therapy TSAT values of Group II was significantly different from that 
of Group I (p = 0.017). There was no significant difference in the post-therapy 
TSAT values between Group II and III or between Group I and III (p = 0.951, 0.078 
respectively). 
 When a difference in difference analysis was carried out, the rise in TSAT 
values of Group II  and III were significantly more than that observed in Group I  
(p = 0.008, 0.03 respectively). 
 There was no significant difference in change in TSAT values observed 
between Group II and III (p = 0.983). 
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ADVERSE DRUG REACTIONS 
 12 participants reported adverse effects to their medication. Most of the 
adverse effects were not reported spontaneously. They were reported on questioning 
the participants at the end of the study period. The only exception was a single case 
of gastritis who was treated with H2 blocker during the study period. The group-wise 
split up is presented in the bar diagram below.[Figure 16.] 
 
Figure 16: Bar Diagram of Group-wise Adverse Drug Reactions 
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Common Adverse Drug Reactions (ADR) Reported 
 Gastritis, constipation, nausea, vomiting and loose stools were the side 
effects showed in the participants during the study duration.  
 
Figure 17: Pie Chart of Common ADR Reported  
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DESCRIPTION OF ADVERSE DRUG REACTIONS REPORTED 
Group I (Ferrous Sulphate Arm) 
 9 participants reported adverse drug reaction to their medication. 7 
participants reported gastritis with 2 of them missing 3-4 doses of their medication. 
The remaining 5 had mild bearable gastritis. One of them reported mild gastritis and 
constipation during the first week of treatment. Two other participants reported 
missing their doses for 5 and 3 days dues to constipation and nausea respectively. 
Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
 There were no incidents of gastritis or constipation although one participant 
complained of repeated loose stools a few hours after ingesting her medication. 
There was no increase in frequency of stools. A possibility of lactose intolerance 
was suspected in this participant. The participant did not discontinue her medication. 
Group III (Combination Therapy Arm) 
 Two participants reported occurrence of mild to moderate gastritis, one of 
whom was prescribed T.Ranitdine 20 mg BD concomitantly for a period of 2 weeks. 
There were no reports of change in bowel habits in the participants of this group.   
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ADHERENCE TO TREATMENT REGIMEN 
 Of the 68 participants who were recruited in the study, 66 completed the 
study. The two drop outs belonged to Group III (Combination Therapy Arm). One 
was diagnosed with infective hepatitis and was not available for follow-up. The other 
drop-out resorted to intravenous iron instead of taking her oral medications and 
voluntarily dropped out of the study.  
 Participants were interviewed on their adherence to their 30 day treatment 
regimen. The compliance in Group I (Ferrous Sulphate Arm) was found to be 44% 
which is much lower than that found in the arms recieveing lactoferrin fortified 
bovine colostrum. The compliance in Group II and III were both found to be 94%. 
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DISCUSSION 
 
 Oral ferrous sulphate is the most commonly prescribed drug for treating iron 
deficiency anaemia. The poor compliance, GI adverse drug reactions and the 
variable bioavailability of oral ferrous sulphate emphasize a need for a better oral 
formulation. Lactoferrin, a glycoprotein structurally resembling transferrin, is 
believed to play a role in iron absorption. Previous studies conducted in Italian 
pregnant women and Japanese athletes have shown beneficial effects of bovine 
lactoferrin in treating iron deficiency anaemia. Hence, a randomized, active 
controlled, open-labelled, 3 armed parallel study was designed to compare the 
efficacy of oral lactoferrin fortified bovine colostrum (as single agent and in 
combination with ferrous sulphate) with oral ferrous Sulphate in treating iron 
deficiency anaemia.  
 The prevalence of anaemia amongst nursing students in our study was found 
to be 35%. This is comparable to previous studies conducted in India, that have 
stated that at least 40% of asymptomatic nurses in their study had biochemical 
evidence of iron deficiency anaemia.[23,79]  
 Our results show significant improvement in haemoglobin and most iron 
parameters in participants of Group II (Lactoferrin Fortified Bovine Colostrum Arm) 
and Group III (Combination Therapy Arm) compared to Group I (Ferrous Sulphate 
Arm). 
106 
 The significant increase in haemoglobin and serum iron concentration values 
following therapy in both Group II and III (p <0.05) is in accordance with a previous 
study conducted among pregnant women in Italy in 2006 by Paesano et al who 
reported a mean rise in haemoglobin of 1.5g/dl and a mean increase in serum iron 
concentration of 54.2 mcg/dl.[78] Our study showed a mean rise in haemoglobin of 
0.9288g/dl  and a mean rise in serum iron concentration of 18.4952 mcg/dl in Group 
II.[Table 9] Group III showed a mean rise in haemoglobin of 1.0625g/dl and mean 
rise in serum iron concentration of 17.3575mcg/dl.[Table 11] The mean rise in 
haemoglobin and serum iron concentration in our study is lower compared to the 
Italian study which may be explained by the higher dose of lactoferrin employed in 
the latter study. Though our rise in haemoglobin and serum iron concentration 
values are lower than their study [78], the rise observed in Group II and III are both 
clinically and statistically significant. (p < 0.05)  
 The participants in the ferrous sulphate arm failed to register improved 
haemoglobin levels and iron parameters. This is in accordance with a study 
conducted in Italian pregnant women in 2010 who were prescribed 156 mg of 
elemental iron for 30 days. This study documented a parallel fall in serum IL-6 
levels which may lead to a hepcidin mediated down regulation of ferroportin 
resulting in decreased enteral iron absorption. [77] 
 The rise in haemoglobin (0.028g/dl) in Group I much less than a previous 
study (1.05 g/dl) conducted among pregnant women in India in the Guntur District 
by Chandrakala Kambar et al.[80] This disparity may be attributed to better 
compliance and longer duration of therapy amongst the pregnant women.  
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 On the contrary, the mean rise in serum iron concentration in our study 
(1.544 mcg/dl) is thrice that reported by their study (0.5 g/dl).[2] This may be due to 
increased utilization of iron resulting in minimal rise in serum iron concentration in 
pregnant women of that study.  
 The marginal rise in haemoglobin (0.028 g/dl, p = 0.717) and serum iron 
concentration (1.544 mcg/dl, p = 0.752) in Group I was significantly lower 
compared to Group II and III ( p <0.05).  Hence it is evident that lactoferrin fortified 
bovine colostrum has resulted in a rise in serum iron concentration that has 
translated into improved haemoglobin levels.  
 The change in ferritin levels following therapy is not statistically significant 
in all the three groups. This may be due to the fact that at least a three month course 
of therapy is required for restoring iron stores in the body.[81] Ferritin levels have 
been noted to rise as early as 2 weeks in an ICMR study conducted by Alka Kriplani 
et al., where the route of administration was found to be intravenous which has a 
higher bioavailability than the oral route.[27] Another study conducted by Natsue 
Koikawa et al amongst Japanese runners, comparing efficacy of  lactoferrin and oral 
ferrous sulphate reported a decrease in ferritin stores in both the arms after 8 weeks 
of therapy. [82] Our study was designed along the lines of the Italian study 
conducted by Pasaeno et al., who recommended a one month course of oral 
lactoferrin. Hence as our study was designed for a period of one month, and as the 
route of therapy was oral, the change in ferritin is along the expected lines.  
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 Serum iron concentration has an inversely proportional relationship with 
TIBC and UIBC and hence the marginal rise in serum iron concentration in the 
ferrous sulphate arm is only associated with a marginal fall in TIBC and UIBC.[86] 
The significant fall in TIBC and UIBC observed in the test arm and the combination 
arm is in agreement with a previous Italian study by Nappi et al. [83] The Italian 
study documented significant fall in TIBC even in the ferrous sulphate arm which 
also demonstrated significant rise in serum iron concentration. 
 Group II and Group III demonstrated a significant rise in transferrin 
saturation (p  < 0.05) which paralleled an increase in serum iron concentration levels 
in both the groups. This significant improvement is contrary to what was observed 
amongst cancer patients with anaemia of chronic disease who were given 200 mg of 
lactoferrin along with erythropoietin.[84] Hence the beneficial effect of lactoferrin 
that is seen in cases of nutritional iron deficiency does not extrapolate to Anaemia of 
Chronic Disease.  
 There was no significant difference in the iron parameters and haemoglobin 
levels from base line to post-therapy between Groups II and III thereby quelling any 
belief on the possible haematological benefits of combining ferrous sulphate and 
lactoferrin fortified bovine colostrum.  
 The participants who received lactoferrin fortified bovine colostrum reported 
fewer adverse effects (4%, 13%) than those on ferrous sulphate (36%). This is in 
accordance with previous studies that have also noted considerable  adverse effects 
with ferrous sulphate.[85]  The most common adverse effect reported in this study 
was gastritis, followed by altered bowel movements. Further studies are required to 
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determine the role of lactoferrin fortified bovine colostrum in reducing the incidence 
of adverse drug reactions when given in combination with ferrous sulphate as has 
been demonstrated by the lower incidence of adverse effects reported in the arm that 
received both. 
 Significant improvement in haemoglobin and iron parameters were observed 
in participants who received lactoferrin fortified bovine colostrum either as a single 
agent or in combination with ferrous sulphate. 
 The mechanism by which lactoferrin improves iron parameters and 
hematologic parameters is yet to be understood. The iron binding capacity of 
lactoferrin, the iron content of lactoferrin fortified bovine colostrum or the IL-6 
mediated hepcidin regulation may contribute to the effect of lactoferrin in iron 
metabolism. 
 A lower incidence of adverse drug reactions amongst participants on 
lactoferrin fortified bovine colostrum further justifies the utility of lactoferrin 
fortified bovine colostrum in correcting iron deficiency anaemia. 
 A study of larger scale may be carried out to further ascertain the efficacy of 
lactoferrin fortified bovine colostrum in treating iron deficiency. Further studies 
with purified lactoferrin are warranted to avoid difficulties in interpretation of the 
data. A study duration of at least 3 months or more would be desirable to assess the 
effect of lactoferrin on iron stores. Zinc protoporphyrin assay and RBC indices and 
counts would provide a better assessment of iron status of an individual.  
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CONCLUSION 
 
 Iron deficiency affects more than 2 billion people globally, with greater 
prevalence noted amongst women and children. When left untreated, it is associated 
with easy fatigability, decreased work performance, poor pregnancy outcomes and 
delayed developmental milestones. Hence it is imperative to rectify the iron 
deficiency in an individual. Oral ferrous sulphate, the most commonly prescribed 
drug for treating this condition, is associated with 25 to 40% incidence of adverse 
effects.  This along with its variable bioavailability emphasise a need for better oral 
formulations. Lactoferrin, a glycoprotein structurally resembling transferrin, is 
believed to play a role in iron absorption.  Previous studies conducted in Italian 
pregnant women and Japanese athletes have shown beneficial effects of bovine 
lactoferrin in treating iron deficiency anaemia.  
 Our study results demonstrate significant improvement in iron parameters 
and haemoglobin levels in those on lactoferrin fortified bovine colostrum compared 
to oral ferrous sulphate. The participants on lactoferrin fortified bovine colostrum 
reported fewer adverse effects and adhered to their treatment regimen more 
faithfully compared to those on the ferrous sulphate regimen. No improvement in 
iron and haematological parameters was noted on addition of ferrous sulphate to 
lactoferrin fortified bovine colostrum though the combination demonstrated lower 
incidence of adverse drug reactions.  
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 Hence lactoferrin fortified bovine colostrum is more efficacious is treating 
iron deficiency anaemia compared to oral ferrous sulphate and is associated with 
fewer adverse drug reactions and greater compliance making it a suitable alternative 
to the current treatments available. 
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Patient Information Sheet 
 Anaemia is a disease that presents with easy fatigability, lack of vitality, 
weakness, faintness, palpitations, headache and breathlessness, palpitations. 
 It is caused by reduced amount of haemoglobin in red blood cells which are 
instrumental in delivering oxygen to your tissues.  
 Laktrum is bovine colostrum fortified with lactoferrin. Laktrum is a natural 
nutritional supplement providing rich nutrients that promote immunity, growth and 
good health. Colostrum is found in first 24-36 hrs of mother’s milk and is rich in 
vitamins and minerals. 
 Lactoferrin in bovine colostrum will increase the absorption of iron from 
your body and hence result in increased synthesis of haemoglobin.  This will result 
in better oxygen delivery to your tissues and make you feel less tired, and more 
active. 
 Laktrum does not contain any substances that can induce allergy and is safe 
for consumption. 
 Take 2g (one spoonful) of laktrum and mix it in one cup water or milk. This 
is to be taken at bedtime for a period of 30 days. 
 
PATIENT CONSENT FORM 
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Study Title : Comparative Study of Efficacy of Lactoferrin fortified bovine 
colostrum with Oral Iron in the Treatment of Iron Deficiency 
Anaemia 
Study Center:  Kilpauk Medical College and Hospital, Chennai-10 
Patient Name :      O.P. No.: 
Patient Age/sex: 
 I confirm that I have understood the purpose and procedure of the above 
study. I had the opportunity to ask questions and all my doubts have been answered 
satisfactorily.  
 I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without my legal rights being affected. 
 I understand that the sponsor of the clinical study, members of the ethical 
committee and the investigators involved in the study will not need my permission 
to look at my health records, both in respect to the current study and any other 
further research that may be conducted in relation to it. However, I understand that 
my identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any data 
or results that may arise from this study. 
 
 I hereby consent to participate in this study. 
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 I hereby give permission to undergo complete clinical examination and 
diagnostic tests including withdrawal of 8ml of blood at the beginning and end of 
the study. 
Patient Signature/ Thumb Impression : 
Patient Name and address : 
Witness Signature/ Thumb Impression : 
Witness Name and address : 
Investigator’s Signature : 
Name of the Investigator : 
Place: 
Date: 
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COMPARATIVE STUDY OF EFFICACY OF LACTOFERRIN FORTIFIED 
BOVINE COLOSTRUM WITH ORAL IRON IN THE TREATMENT OF 
IRON DEFICIENCY ANAEMIA 
CASE REPORT FORM 
Name  :    D/O: 
Age  : 
Sex  : 
Address : 
Ref No. : 
History : 
Past H/o : 
H/o of bleeds : 
H/O of Renal or Liver disease : 
H/o of Blood transfusion : 
H/o of medication : 
Past Medical H/o : 
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Signs 
General:  Pallor:  Icterus: Clubbing: Cyanosis: Edema: 
Vitals: BP:  PR:   Temp:  
CVS : 
R.S : 
P/A : 
CNS : 
Investigations 
Test Baseline Post- Therapy 
Peripheral Smear     
Hb%   
Sr. Iron   
Sr. Ferritin   
Transferrin Saturation   
Total Iron binding capacity   
TC   
DC   
ESR   
SGOT   
SGPT   
Bilirubin   
Urea    
125 
Creatinine   
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PLAGIARISM 
CERTIFICATE
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